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The project was developed according to the following phases:
1. Collection of published studies on mortality among drug users.
2. Critical revision of the methods used and the results obtained in the selected studies.
3. Oganization of a meeting to discuss the major issues to be taken into account for developing a
standardized methodology to assess overall and cause-specific mortality rates among drug users
in Member States of  European Union.
4. Draft of a standardized protocol for a cohort mortality study among drug users in different
European Countries.
LITERATURE REVIEW OF SCIENTIFIC STUDIES ON
OVERALL AND CAUSE SPECIFIC MORTALITY AMONG
DRUG USERS
Introduction
1. Source of mortality data
Mortality data can be generated from two basic types of study:
a) cross-sectional studies
b)  longitudinal studies
The cross-sectional studies measure all drug-related deaths occurring in a particular area and
in a specific period of time. The value of this kind of study mainly depends on the accuracy in
identifying addict deaths and specifying both the criteria of classification of drug-related death and
the source of data.
In longitudinal studies, a specific group of addicts (generally enrolled at treatment centres)
is followed over a definite time period of years. This kind of studies provides accurate data on the
outcome of addiction within a particular group and it is the only one that allows to estimate the
actual overall and cause-specific mortality rates.
2. Data on drug related deaths: problems of definition
In most European countries different sources of data on drug-related deaths are available,
such as public health authorities, the police or the judiciary, and yield annual figure. It is, however,
debatable whether they can be used to describe the extent and pattern of drug-related deaths in each
countries and whether these figures are comparable because of the lack of both consensus regarding
the definition that should be applied to such deaths and a common classification. The criteria for the
definition of "drug-related death" can be based on:
(a) clinical and toxicological criteria, such as the type of substance used and the route of
administration;
(b) the circumstances surrounding the death;
(c) person known as a drug addict.
Different European countries places emphasis on the various aspects of these criteria and
consequently the definitions of drug-related death adopted in various countries may differ.
Moreover, epidemiological assessment of drug-related deaths may even be difficult within a given
 country because data from different sources (i.e. death certificates or records of a ministry of health
and a ministry of justice) can produce very different estimates.
Different types of death can be considered as "drug-related" and the following  is only one of the
possible classifications:
 deaths due to massive intoxications or overdoses
 suicide related to drug dependence
 deaths due to accidents and violence influenced by drug use
 deaths due to long-term abuse of drugs
 deaths due to behaviour associated with drug use
Although most European countries have national and/or regional mortality registers where
deaths are coded on the basis of the International Classification of Disease (ICD), the heterogeneity
of  "cause" of death definition and, consequently, of the codes applied, make it difficult to compare
consistent estimates of deaths among drug users.
3. Mortality of Drug Users: determinants of estimates
Different factors can affect the estimate of mortality of drug users (figure 1).
The first step should be the identification of the actual population of drug users out of the
overall population. The use of psychotropic drugs in Europe is an illicit behaviour, even though with
different levels of tolerance, therefore drug users can be considered a hidden population. The
available observation systems only allow  to identify drug users referring to health services for either
treatment for drug abuse or health problems related to their drug use. Therefore, different variables
affects the likelihood of identifying drug users:
a) the potential for harm of the drug used, itself depending on biological, social, environmental and
behavioral factors;
b) the availability of health services;
c) the accessibility and acceptance of health services.
The second step is the identification of deaths among drug users. Mortality of drug users
depends on both prevalence of drug users and lethality. Determinants of prevalence have been
already discussed. Lethality of drug users is affected by:
a) the actual harm of drug use
b) the availability of health services
c) the effectiveness of health services.
The identification of deaths among drug users depends on the available monitoring systems.
Most of them measure deaths directly related to drug use without a standard definition of "case" not
only across countries but also within countries. Furthermore, the national mortality monitoring
systems, although using standardized methods to measure causes of deaths, do not provide a specific
code for deaths occurring among drug users.
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Eventually, what is usually available is the number of drug-related deaths over the general
population.
This indicator might be heavily biased, both in geographical and temporal comparisons, by
the following factors:
- heterogeneity of occurrence of drug use
- heterogeneity of determinants of health of drug users
- heterogeneity of effectiveness and/or availability of health services
- heterogeneity and/or validity of "case definition" of drug-related death
Sometimes estimates are provided of "rates" of drug-related death over the observed
population of drug users, using estimates of both numerator and denominator coming from
independent sources. In other terms it is not satisfied the condition that cases (deaths) must come
from the study population;  the latter indicator , therefore, cannot represent a valid estimate of
mortality of drug users.
4. To estimate overall and cause-specific mortality rates among drug users
Most of knowledge available on mortality of drug users comes from measure of directly  and
indirectly drug-related deaths, in terms of rate over the general population but only longitudinal
studies can measure the actual mortality rate among drug users. This is a major epidemiological task
because reliable data are difficult to gather.
Mortality in the general population is currently measured; the denominator is an estimate
of the resident population in a defined time and place and the numerator is the corresponding
number of deaths. The requirements for measuring mortality rates in the general population are:
 the availability of an estimate of resident population at mid-time;
 a comprehensive ascertainment of vital status for the corresponding period;
 coding of causes of death.
The requirements needed to estimate mortality among overall and actual population of drug
users are both missing. We do not have currently both measures:
a) the size of the resident population of drug users
b) comprehensive ascertainment of vital status
As far as the latter issue is concerned, there is no code of the International Classification of
Diseases specific for intravenous use of drugs; therefore it is only possible to measure deaths
classified as those relating to drug dependence (ICD IX: 309) or among those relating to injury and
poisoning (ICD IX: 965). We have already stated that different sources of data for overdose deaths
are available, but their validity is extremely heterogeneous over time and space. For instance, official
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reports from hospitals or medical examiner offices are incomplete in their coverage of drug related
incidents. Another limitation of using "drug-related" deaths to approximate mortality of drug users,
comes from the evidence that drug users do actually die also from other causes. The proportion of
deaths coded as death due to drug dependence and poisoning by opiates and related narcotics -
respectively ICD IX 304.0-304.9 and 965.0 - out of the total deaths, estimated in a multicentric
cohort study on  mortality of drug injectors, ranged from 0 in New Haven to 46.7% in  Liverpool
during the period 1980-1992.
In conclusion, mortality cohort study can be considered the most valid and reliable study
design to investigate the health effects of drug abuse and their heterogeneity.
Some limitations of longitudinal studies must be considered:
 the study population is always a "selected" group of known drug users. It can not be excluded
that the selection factors for including in the cohort population could be themselves
determinants of mortality. Maximum effort must be made to check whether the study population
can be considered representative of the actual population of drug users.
 mortality rates of causes of death/diseases which are amenable for medical and/or emergency
treatment can be seriously biased, in time and space comparisons, by the heterogeneous
availability and/or effectiveness of health services
 limitation of extent and duration of follow-up and proportion of drug users lost to follow-up
could bias the mortality estimates.
Moreover, specific attention must be paid in adopting procedures and methods to protect
privacy of drug users.
Published studies on mortality among drug users were identified through computerized
searches (MEDLARS databases) from January 1980 till December 1996, using the subject headings
of:
Also, a handsearch of the studies published before 1980, has been conducted following the
references in the papers selected through the computerized searches. The latter method have not
yield an exhaustive list of papers on mortality of drug users, but we have traced the most quoted and
significant papers published between 1965 and 1979. Searches were limited to English language
publications.
Out of 340 papers that were identified, 66 have been selected to be reviewed because of 
NUMBER OF PAPERS COLLECTED
                European countries        Other countries
Longitudinal studies                     24                                   9
Cross-sectional studies                 14                                   6
Case-control studies                       1                                   1
Letters, editorials and reports      7                                    4
        
their relevance for the project. A total of 20 papers dealing with studies carried out in countries
outside Europe have been included because of their particular significance. Letters, editorials and
reports have been also included because of their contribute in clarifying some important issues
related to drug users mortality. The results of the searches are summarized in the following tables:
The complete and chronologically ordered list of the references on mortality among drug
users that will be reviewed is included (see APPENDIX).
The items according to which each paper was reviewed are the following:
Longitudinal studies Cross-sectional studies
- Authors and year (Ref. N) - Authors and year (Ref. N)
- Study site - Study site
- Study population - Source of data
- Number of subjects - Study period
- Follow-up period - Number of deaths
- Findings - Findings
- Comments - Comments
For longitudinal studies a more detailed review was carried out taking into account methods
used to ascertain vital status and causes of death.
Comments
Cross-sectional studies
Twenty-one papers regarding cross-sectional studies have been published between 1970 and
1996. Fifteen studies out of 21 have been carried out in European countries: United Kingdom,
Denmark Norway, Austria and Spain.
Very heterogeneous sources of data have been used:
- clinical records
- coroners' registers
- autopsy reports
- police reports
- treatment services records
- toxicological laboratories
- national or local population registers.
The characteristics of the sources of data, criteria and modalities for selecting cases have not
always been well specified. The definition of "drug-related" death and more specifically the criteria
adopted to distinguish "directly" or "indirectly" drug-related deaths are very heterogeneous among
different studies. Furthermore, there are differences as regards the classification of causes of deaths
because only in few cases ICD codes have been used.
 In a few studies the authors critically pointed out the limits of the sources of data used in
describing mortality among drug users.
In most of the studies reviewed, mortality rates have been calculated using different
populations at risk as denominator such as number of addicts notified to local or national drug
dependence registers, mid-year population resident in a country or in a particular area or, more
recently,  population of drug users (injectors) estimated with capture-recapture method.
Mortality "rates" obtained by relating the number of "drug-related" deaths to a population
at risk different from the population generating the cases, can not be considered valid estimates of
mortality of drug users. In this case, in fact,  the condition that cases (deaths) must come from the
study population it is not satisfied.
Longitudinal studies
All cohort studies on mortality among drug users  show death rates higher than expected in
a matched general population group, although there is variability across study periods, study
population and location.
The following analysis describes the heterogeneity of longitudinal studies reviewed, in terms
of study population and methods used to ascertain vital status and causes of death.
Out of 32 papers reviewed, 20 were published between 1987 and 1996, as shown in the
following scheme:
Year of publication n°
1966- 1976 4
1977- 1986 9
1987- 1996           20
As regards the study site 23 studies were carried out in European countries and more
specifically: 7 in Great Britain, 10 in Northern Europe (Sweden, Norway, The Netherlands,
Denmark and Germany) and 6 in Southern Europe (Spain and Italy).
Longitudinal studies carried out in different countries are heterogeneous in terms of study
population, criteria for enrolling subjects, methods used to ascertaining vital status and causes of
death as well as methods of analysis.
Mortality rates have been estimated almost exclusively among drug users receiving
treatment since identifier information are necessary to ascertain their vital status. In most cohort
studies the study population has been enrolled among those who were attending treatment centres
as outpatients. Only in few studies (5 out of 32), subjects included in the cohort have been selected
among those hospitalized with diagnosis of drug addiction; moreover, in five studies both inpatients
and outpatients have been enrolled.
The study population differs among countries with regard to type of drug used and route of
administration. In 6 studies out of 32, type of substance abused has not been specified and in 9
studies drugs are generically reported as "narcotics" or " opiates". In most of the studies, use of
heroin, alone or associated with other substances, was the first requirements for recluting subjects
into the cohorts. In less than half of studies (14 out of 32), the route of administration is specified
(mainly by injection or injection and other).
In 31 studies out of 32, methods used for ascertaining vital status have been specified but
with some differences with regard to the description of characteristics of data sources. The  most
frequent sources of information on vital status used in longitudinal studies are local or national
population registers, hospital and drug treatment services records and central police registers. In
addiction to these sources of data, in a few studies, information on vital status have been obtained
through interviews and visits. The latter method for tracing subjects has been used especially in
those longitudinal studies that were carried out with  not only the purpose of measuring mortality
rates but also to detect other addiction outcomes such as abstinence, or continued drug use and
treatment centres attendance.
Ascertainment of causes of deaths has been performed in 29 studies out of 32 using different
sources. Information have been obtained from national or local mortality registers where available,
hospital and medical examiner reports, coroners' reports and directly from deaths certificates. Only
in few studies causes of death have been identified according to the International Classification of
Diseases (ICD) and even where official statistics have been used not always ICD codes were
specified.
In conclusion, the heterogeneity of methods used to carry out longitudinal studies hampers
geographical and temporal comparisons and calls for developing a standardized methodology.
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REVIEW OF
LONGITUDINAL STUDIES
LONGITUDINAL studies
Authors and year (ref.
N)
Vaillant GE , 1966 (1)
Study site USA (Kentucky)
Study population All male narcotic addicts (28-35 years) coming from NY and admitted to the Lexington Hospital, Kentucky, + a
group of unselected male addicts from NY (reference group) "first admitted" to the same hospital in the same
period  (1.8.53-31.1.53).
Participants were classified as abstinent, addicted or possibly addicted, instituzionalized, marginal.
N° of subjects 50 + 100
Follow-up period From date of enrolment till 1964-65. All participants has been followed for a minimum of 9 years after discharge
and at least until the age of 39.
Findings Among the 132 subjects followed for 12 years, 20 died (12 from the study group and 8 from the reference group).
Death rate was three-fold that expected for males of similar age; the death rate for alcoholism complication was
very high.
Comments The study group was biased by containing readmission and was confined between the ages of 28 and 35.
The study group contained 18 members of the reference group.
LONGITUDINAL studies
Authors and year (ref.
N)
Bewley TH, Ben-Arie O, James P, 1968 (3)
Study site Britain
Study population All case of heroin addiction first known to the Home Office from 1947 to 1966 (therapeutic and non therapeutic).
N° of subjects 1272 (1237 therapeutic, 35 non therapeutic)
Follow-up period 1954-1964
Findings 69 deaths among non-therapeutics, 16 among therapeutics. Increase in the number of deaths and a decrease in
the mean age of death (55% of deaths under 28 years).
Mortality rate: 27 per 1000 per annum, 28 times the normal rate in the similar British population  and 2 times that of
heroin addicts in New York. 1 death for every 37 addicts known to the Home Office.
Causes of death: 39% overdose (16 accidental, 7 with suicidal intent), 22% violent death (9 suicides), 22%
infectious disease, 17% natural death (directly or indirectly due to drug addiction).
Comments
LONGITUDINAL studies
Authors and year (ref.
N)
Bewley TH, Ben-Arie O, 1968 (4)
Study site London, (United Kingdom).
Study population Male heroin addicts discharged from Tooting Bec Hospital between 01.10.64 and 31.12.66 (all non therapeutic
addicts with 1-2 years of addiction at first admission)
N° of subjects 100
Follow-up period From enrolment to January 1967-January 1968.
Findings 13 deaths (per 100). Causes of death: 8 overdose, 2 septic pneumonia, 1 suicide, 2 other violent deaths.
Comments The population is possibly not representative of all the heroin addicts, but is probably representative of the less
successful, more ill and more disturbed younger British addicts.
LONGITUDINAL studies
Authors and year (ref.
N)
Watterson O, Simpson DD, Sells SB, 1975 (9)
Study site Texas (USA)
Study population All addicts using opioids daily at time of admission to treatment in the Drug Abuse Reporting Program (DARP) file
admitted or continuing a treatment during a 1 year interval over a period of three years.
N° of subjects  I period ('70-'71): 9276, II period ('71-'72):17684, III period ('72-'73): 23529 (not mutually exclusive)
Follow-up period 1.06.70-31.05.71 - 1.06.71-31.05.72 - 1.06.72-31.05.73
Findings Number of death (Death rates per 1000): I period: 50 (15); II period: 91 (12); III period 134: (13).
Death rates for all periods combined: 13 per 1000 (275 deaths), 14 per 1000 for males, 9 per 1000 for females,
higher for age >30.
Decrease in death rates for people in Methadone Maintenance, low death rates for people in Therapeutic
Community.
Causes of death: 40% violent, 33% drug related, 23% others, 4% unknown.
Comments Death rate = number of deaths/total man years at risk per 1000. Time at risk = time in treatment.
Understate the death rates for people in the street. Changes in the number of agencies and governmental
guidelines.
LONGITUDINAL studies
Authors and year (ref.
N)
Thorley A, Oppenheimer E, Stimson GV, 1977 (10)
Study site London (England)
Study population People attending 13 Drug Dependence Clinics (DDCs) for whom heroin was prescribed as outpatients between
March and November 1969
N° of subjects 128
Follow-up period October 1969 - October 1975.
Findings 12 (9%) were dead; 65 (51%) were attending clinics; 51 (40%) were alive and not attending the clinics. About 33%
of the sample were still receiving heroin or prescription, and 23% had received heroin without interruption since
1969.
Comments Weakness of data from Home Office: they don't know the current status of almost half the sample.
LONGITUDINAL studies
Authors and year (ref.
N)
Stimson GV, Oppenheimer E, Torley A, 1977 (12)
Study site London (England)
Study population see reference n. 10
N° of subjects 128
Follow-up period Second follow-up between June 1976 and November 1977
Findings 4 people was lost at follow-up. 52 people (41%) had stopped attending the clinics, 6 (5%) were in prison, 55 (43%)
were still attending the clinics and 15 had died. 31% reached abstinence from opiates, 48% was still using.
Death rate = 16.7 per 1000 per annum. Most common cause of death: respiratory failure due to opiate and
barbiturate poisoning.
Comments Follow-up with a high rate of personal contact.
The sample represented the 11% of the total DDCs population in England and Wales.
All people dead were drug dependent at the moment of death.
LONGITUDINAL studies
Authors and year (ref.
N)
Wiepert GD, Bewley TH, d'Orban PT, 1978 (13)
Study site London (England)
Study population All patients attending two drug clinics in London, for treatment of opiates dependence, between 1968 and 1975. In
1968 95% depending from heroin, in 1975 98% depending from methadone.
N° of subjects 575
Follow-up period 1968-1975
Findings 52% still in treatment, 11% died, 6% in custody, 3% left the country, 28% left the treatment or lost.
Drug abuse was the principal cause of death.
Comments The rate of death was many times higher than might be expected for the same age group.
Those who died had been more inconsistent in attendance, had abused drugs more and had a lower rate of
employment.
LONGITUDINAL studies
Authors and year (ref.
N)
Concool B, Smith H, Stimmel B, 1979 (14)
Study site New York (USA)
Study population All heroine addicts admitted for the first time to the Methadone Maintenance and Aftercare Treatment Program
(MMATP) between March 1
969 and December 1976 + a control group randomly selected from the entire clinic population.
N° of subjects 1156
Follow-up period March 1969 - December 1976
Findings 45 death (39 per 1000): 23 (20 per 1000) died while in program, 22 (19 per 1000) died after discharge.
Cause of death: 38% violence, 40% medical complications, 9% accidents, 13% overdose.
60 % of deaths was attributable to alcohol. The group of control and the decedents differed by alcoholism, age on
dimission, length of addiction, solitary lifestyle.
Comparison of death rates between people from MMATP and East Harlem population differed by cause of death
when adjusting for age.
Comments The control group was selected so that the number of controls in a year was proportional to the number
of deaths in that year.
Methadone was never implicated as a causative factors of death.
LONGITUDINAL studies
Authors and year (ref.
N)
Wille R, 1981 (15)
Study site London (United Kingdom).
Study population see ref N. 10
N° of subjects 128
Follow-up period 1969-1979
Findings 19 (15%) deceased, 49 (38%: 24 persons were being prescribed heroin, the rest methadone only) still attending,
60 (47%) discharged.
Death rate= 14.8 per 1000 heroin addicts yearly.
Cause of death: 8 respiratory failure due to poisoning, 5 other illness, 2 accidents, 1 suicide, 3 drug addiction
Comments
LONGITUDINAL studies
Authors and year (ref. N) Musto DF, Ramos MR, 1981 (16)
Study site New Haven, Connecticut (USA)
Study population Morphine addicts registered at the New Haven Narcotic Clinic as of May 1920
N° of subjects 91
Follow-up period 29.05.1920 - 1972
Findings 40 death (all white): 51% of the white people, 44% of the total population. The 35 men died 12 years earlier than
expected, mean age 57; the 5 women died 18 years earlier than expected, mean age 51.
Alcoholism, cyrrosis, suicides, accident and veneral diseases accounted for 26% of death causes, compared to
9% of the population of Connecticut of same age. Tuberculosis accounted for 10%, versus 3%.
Comments Number of expected death was calculated on the basis of the life expectancy related to the age of the subjects in
1920.
No death could be ascribed to overdose of an opiate.
LONGITUDINAL studies
Authors and year (ref. N) Joe GW, Lehman W, Simpson D, 1982 (20)
Study site USA
Study population Samples of opiates abusers admitted to community-based treatment programs + a comparison group that didn't
receive treatment between 1969 and 1973 (DARP).
N° of subjects 6402, 5340 were located, 78 were excluded for miscellaneous problems, for a total of  5262 .
Follow-up period From enrolment to 1975-1979
Findings 179 deceased in the first 4 years of follow-up, yielding a death rates of 15.2 per 1000 person-years at risk. When
adjusted for age, death rates were found to be 3 to 14 times greater than those in the general US population.
Mortality rates were significantly higher for older clients and for heavier alcohol users. Among the variables
significantly correlated to survival  curves there were: age at DARP admission, pre-DARP alcohol consumption,
year of admission to DARP treatment.
Causes of death: 28% violence related, 44% drug-related, 17% natural causes, 11% unknown.
Comments Classification of causes of death  were based on death certificates (four categories: violence, drug abuse related,
other causes, unknown).
Mortality was investigated using life-table analysis (cumulative survival rate for different group).
Death rates were computed as the number of deaths/person-years following treatment per 1000.
Located cases were used as the population base for computation of death rates.
LONGITUDINAL studies
Authors and year (ref. N) Benson G, Holmberg MB, 1984 (23)
Study site Denmark (Gothenburg)
Study population Selected (persons in treatment not older than 25) and unselected drug users from the same area
N° of subjects UNSELECTED: 1) 4783 pupils in 9th grade school; 2) 2658 military conscript.
SELECTED: 3) 213 drug clinic outpatients; 4) 58 psychiatric inpatients diagnosed drug abuse;  
                         5) 231 admitted at drug rehabilitation home; 6) 263 from social welfare files.
Follow-up period 1) 1969-78; 2) 1970-78; 3) 1968-78; 4) 1968-78; 5) 1970-79; 6) 1968-78.
Findings 44 deaths (19 among unselected population, 25 among selected one). A higher mortality was observed n the
selected groups;
3) 4.7 times the expected in males;  5) 6.9 times in males, 7.9 times in females; 6) 2.4 times in males.
Causes of death: UNSELECTED : MALES: 5 suicides, 6 accidents, 1 alcohol consumption;
                                                                      FEMALES: 5 suicides, 2 accidents. 
                                   SELECTED:         MALES: 12 suicides, 11 accidents, 1 cardiac disease, 1 pyelonepritis.
Comments The expected age-related mortality was calculated for the selected groups using average from 1969, 1973,1978.
Expected mortality for different causes was calculated using data from age 15-24 years, and the period '69-'79 as
a basis.
Addicts in the unselected groups used cannabis, solvents, LSD, central stimulants.
Addicts in the unselected groups were polydrug abusers, including alcohol and a high frequency of central
stimulants.
LONGITUDINAL studies
Authors and year
(ref. N)
Haastrup S, Jepsen PW, 1984 (24)
Study site Denmark (Copenhagen)
Study population People in treatment for morphine abuse from Copenhagen Community Hospital and Drug Treatment Service.
N° of subjects 300
Follow-up period 1973-1980 (seven years after the first referral to treatment).
Findings 203 (68%) men and 97 (32%) women. The median age at start of daily intra venous use was 17 years and the median age at first referral
to treatment was 21 years. Less than one sixth of the original population could be described at the time of f-up, as an active addicts. 47
deaths.
Each year 5-6% of the original population had become drug-free and approx 2% had died. Mortality among the remaining active addicts is
rising from year to year, as the active abuser population has strongly declined during the 7-year observation period. Similarly, the
percentage of new long-term drug-free cases from the remaining abuser population is rising from year to year.
In terms of start of drug abuse the average death rate is 2.3% and the average rehabilitation rate 4.0%.
Causes of death: 2 (4%) natural deaths, 10 (21%) accidents, 12 (26%) suicides, 23 (49%) unexplained. Among these, 46% was due to
overdoses (intentional or accidental).
Comments The inclusion criteria were a daily intravenous abuse and a first referral to treatment. The study's most important information was obtained
at face to face interviews (prior to the  interviews information was gathered from the official sources).
The main objective of the study was to describe the progress of the study population during the follow-up period. Because of the lack of any
standard rating scale or general rules, a classification scale was constructed on the basis of a combination of drug abuse and occupational
status in 1980. The scale had four main classes with 10 subclasses levels.
LONGITUDINAL studies
Authors and year (ref.
N)
Joe GW, Simpson D, 1987 (27)
Study site USA
Study population Black and white males selected from the DARP population (see ref n.20)
N° of subjects 697
Follow-up period 6 years extension of the DARP follow-up (6th- 12th year).
Findings 52 deaths, corresponding to 13.8 per 1000 person-years (lower than the previous: 15.2 per 1000)
The average annual risk of death was 1.39%.
Causes of death: 28.8% violence-related; 48.1% drug-related, 23.1% others.
Comments 142 (20%) persons lost at follow-up could have been yielded a bias in the mortality rates (small since lost persons
didn't differ from the others in the principals characteristics). Mortality rates could be influenced by community and
environmental factors.
LONGITUDINAL studies
Authors and year
(ref. N)
Tunving K, 1988 (29)
Study site Sweden (Lund)
Study population Drug addicts admitted to a ward for treatment, offering treatment and detoxification at St. Lars Hospital 
from 1.07.70 to 1.07.78.
N° of subjects 524 (191 opiate abusers, 197 amphetamine abusers, 136 mixed abuse).
Follow-up period From the enrolment to 1.07.84
Findings 62 deaths, corresponding to a death rate of 12 per 1000 (more than 3 times higher than expected). The 62 addicts died
at an average age of 28 years. Opiate addicts had the higher death rate (24/1000 males, 14/1000 females), while
stimulant abusers had the lower 10/1000 in males, no deaths in females). The difference between opiate addicts and
amphetamines abusers was significant (P< 0.001).
The number of deaths increased during the first 6 years (the period when all in the sample were followed-up),  then the
death rate decreased a little.
Causes of death: 19 suicides, 35 drug-related due to overdoses or intoxications, 8 drug-related due to accidents and
violence.
Comments Man-years were calculated as the exposure to risk of death. Expected deaths were taken from the death risk in the
official statistics for the Swedish population in the median year of follow-up (1975).
LONGITUDINAL studies
Authors and year (ref.
N)
Haastrup S, Jepsen P W,  1988 (31)
Study site Denmark (Copenhagen)
Study population Young opioids addicts attending Drug Treatment Service or Mental Hospital in Copenhagen.
N° of subjects 300
Follow-up period 1973-1984
Findings 78 (26%) died. The deaths were distributed evenly over the 11 year period yielding an average mortality of the
cohort of 2.4% per year.
Among those who died in the period 1980-84, 69% died from drug overdose or other causes linked with
intoxication.
In 1984, 24% of the cohort were classified in the best outcome class. Sixteen per cent were classified as
substance users. The number of active drug addicts declines because they died, not because they achieve
abstinence. According to more strict criteria less than 20% would be classified as truly recovered. Another 5-10%
achieve some unstable abstinence.
Comments Criteria of inclusion were daily intravenous abuse of opioids and age less or equal 30. The cohort was followed-up
for a personal interview in 1980 and again in 1984. The interviews were completed with data from various
registers. In 1984, 90% of the cohort was located.
Outcomes were classified on a four-step scale (see ref n. 24) according to current drug status and occupational
status.
Current drug-free status was not validated by urine screening.
LONGITUDINAL studies
Authors and year
(ref. N)
Selwyn PA, Hartel D, Wasserman W, Drucker E, 1989 (33)
Study site USA (New York)
Study population IDUs in a long-term methadone maintenance treatment program.
N° of subjects 900
Follow-up period 1984-1987
Findings 94 died while in treatment. Increase of proportion dying from 13.3 per 1000 in 1984 to 44.2 per 1000 in 1987 (12.9
per 1000 PY in 1984 to 44 per 1000 person-years in 1987).
Causes of death: crude mortality rate for  AIDS increased from 3.6 per 1000 in 1984 to 14.7 per 1000 in 1987.
Smaller or minimal increase was seen for other causes. Cause-specific death rates (in terms of person-years)
among  methadone program patients: AIDS rose from 3.5 per 1000 in 1984 to 14.7 per 1000 in 1987; pneumonia,
endocarditis and bacterial sepsis together:  from 3.5 per1000 in 1984 to 13.5 per 1000 in 1987. Deaths due to
alcoholism/cirrhosis and drug overdose remained relatively constant between 1984 and 1987 (3.5 to 5.7/1000
person-years). Death rates from trauma, including homicide, suicide, and vehicular trauma, showed a slight increase
during the study period (2.4 to 6.8/1000 person-years).
Comments Mortality rates were calculated using the midyear population census as the denominator for each year person-time
was based on time spent enrolled in the methadone program.
LONGITUDINAL studies
Authors and year (ref.
N)
Gronblad L, Ohlund LS, Gunne LM, 1990 (34)
Study site Sweden
Study population Heroin addicts giving methadone maintenance treatment in comparison to street heroin addicts.
N° of subjects 1) 166 Methadone Treatment patients (MT); 2) 34 voluntary discharged; 3) 53 discharged for violation of program
rules; 4) 17 randomized controls; 5) 98 waiting list controls.
Follow-up period 1967-1988. 1) 1967-1979; 2) and 3) from the day of discharging (if a person went back to cohort 1, the second
period was added to the first); 4) starting from the day of randomization; 5) starting the day of referral to MT and
stopped when deleted from the waiting list.
Findings 96 deaths. High significative differences between treated and controls. 1) deaths =16, death rate=1.45, O/E per
year=8.4; 2) 6, 1.65%, 3.8; 3) 26, 6.91%, 55.3; untreated (cohort 4 and 5) 48, 7.2%, 63,1.
Causes of death: majority due to overdoses, mostly by the i.v. route (no overdoses of heroin occurred among those
treated with methadone); suicides: 7 in cohort 1), 1 in cohort 2), 3 in cohort 3).
Comments The 2 control groups didn't significantly differ from each other when their mortality rate was tested according to log-
rank test. These 2 cohorts were therefore combined, forming a group of "untreated controls" (this term should not be
taken literally, since they all underwent intermittent detoxification and participated in drug-free treatment trials, mostly
of short duration.
LONGITUDINAL studies
Authors and year (ref.
N)
Engstrom A, Adamsson C, Allebeck P, Rydberg U, 1991 (36)
Study site Sweden (Stockolm County)
Study population Patients hospitalized with at least  1 diagnosis of drug addiction during 1971-1972.
N° of subjects 1630
Follow-up period 1973-1984
Findings 446 died during follow-up (296 males and 150 females).Overall excess mortality: SMR=5.3. Opiate male users
(mostly by i.v. route) were particularly at risk (SMR= 18.3), and also central stimulant users (SMR=9.0). Average
yearly deaths=2.3%.
Causes of death: mental disorders SMR=43.3 (this group consisted of 52% with an alcohol diagnosis, 19% opiate
diagnosis and 29% mixed abuse); 51% died for injury or poisoning (SMR=17.6); 3.4% died for cyrrosis due to
alcohol; 69% of the patients had committed suicide.
Comments Person-years at risk were computed for each calendar year of the follow-up, distributed by sex and age. 
They used the official death rates for Stockolm County to compare the observed number of death to the expected
ones for the total mortality and the death rates of the whole of Sweden for the mortality by cause of death.
LONGITUDINAL studies
Authors and year (ref.
N)
Perucci CA, Davoli M, Rapiti E, Abeni DD, Forastiere F, 1991 (37)
Study site Rome  (Italy)
Study population IVDUs attending the 3 largest Public Treatment Centres (PTCs) in Rome.
N° of subjects 4200
Follow-up period 1980-1988
Findings 239 deaths (SMR=10.1). Causes of death: overdoses death rate = 3.38  per 1000 person-years; violence =1.62
per 1000 PY,
cyrrosis = 0.88 per 1000 PY; AIDS death rate increased from 0.4 in 1986 to 2.7 per 1000 PY in 1988.
The SMR for all causes was higher among females than among males.
Comments Person -years at risk of dying= from the day of first enrolment to the end of follow-up or to the death.
SMR was calculated to compare observed death to mortality of the national population.
Expected  number of deaths were calculated using sex and age-specific national mortality rates.
LONGITUDINAL studies
Authors and year (ref.
N)
Mientjes GH, van Ameijden EJ, van den Hoek AJAR, Coutinho RA, 1992 (39)
Study site Amsterdam (the Netherlands).
Study population HIV+ (non AIDS) and HIV-  IVDUs recruited at 6 low-threshold methadone outposts  and at a weekly STD clinic for
drug abusers prostitutes
N° of subjects 390 (193 HIV - randomly selected and 197 HIV +)
Follow-up period 1986-1989
Findings 26 (6.6%) died of causes other than AIDS, 17 (8%) were HIV+ and 9 (3.6%) were HIV -.
Causes of death: overdoses, accidents and suicides: 10; unknown: 10.
The overall incidence rate for non-AIDS mortality was 0.023 per PY (N=390) for HIV - and 0.038 per PY (N=420)
for HIV+. RR for HIV+ =1.65 not significant.
Comments Patients who were HIV-infected at study entry and were diagnosed with AIDS during the study period, were
excluded from the study on the date of AIDS diagnosis (to study only non-AIDS mortality).
The Relative Risk refers to the number of hospitalizations of HIV+ compared to HIV -.
LONGITUDINAL studies
Authors and year (ref.
N)
Perucci CA, Forastiere F, Rapiti E, Davoli M, Abeni DD, 1992 (40)
Study site Rome (Italy)
Study population see ref. N 37
N° of subjects 4200
Follow-up period 1980-1988
Findings 213 deaths (SMR=10.5). Excess mortality was found in both sex for all causes (SMR=9.6 males, 20.1 females).
Overdose, violence, cyrrosis, cardiovascular disease and AIDS play a preminent role.
11639 persons aged 15-34 years resulted to be at risk of dying from overdose in Rome, corresponding to an
average annual prevalence of 22.3 per 1000 male and 5.17 per 1000 female.
The deaths attributable to injecting drug use was 16% in male and 9% in females. The cause-specific attributable
proportions were 66% for endocarditis and 37% for cirrhosis in males, and 36% for endocarditis and pneumonia in
females.
Comments To calculate the proportion of all deaths attributable to injecting drug use in the age group 15-34, the formula of the
Population Attributable Risk has been used. The prevalence of the risk factor (i.e. the proportion of IVDUs) in the
general population was estimated using the "multiplier formula" and "capture-recapture" methods.
LONGITUDINAL studies
Authors and year
(ref. N)
Eskild A, Magnus P, Samuelsen SO, Sohlberg C, Kittelsen P, 1993 (41)
Study site Norway  (Oslo)
Study population HIV+ and HIV- IVDU (who had ever injected drugs after 1979, 60% heroin, 10% amphetamine, 30% both) recruited
by the Department
of AIDS prevention, for HIV testing.
N° of subjects 1009 (180 HIV+ AND 829 HIV -)
Follow-up period From the date of the first test until death or the end of follow-up (01.01.91)
Findings 87 deaths. The estimated probability of survival after 3 years follow-up was totally 0.92 (0.87 HIV + and 0.93 HIV -;
difference statistically significant). The RR of death of the total cohort was 31. The highest RR of dying was seen
among HIV + and HIV - females in the youngest age group. The estimated mortality was generally higher than for
the general population.
Causes of death: drug overdose  58 (67%); AIDS: 4; homicides or accidents: 4; other than AIDS: 2.
Adjusted RR of dying from any cause for HIV +: 2.1. The other variables which were significantly associated with
progression to death were >= 30 years of age and >= 5 years of IV drug use prior to study entry. The crude RR of
overdose death for HIV positives compared to HIV negatives was 1.7 and the adjusted RR was 1.4 (not significant).
An IVDUs was defined as a person who had ever injected drugs after 1979.
Comments Mortality rates=number of deaths/ PY during the period for each group of variables (age, HIV status, gender). RR
(compared to the general population )= mortality rates in each group / mortality rates in the general population.
Variables used for the adjusted analysis: gender, age at study entry, duration of IVD, year of study entry.
LONGITUDINAL studies
Authors and year (ref.
N)
Oppenheimer E, Tobutt C, Taylor C,  Andrew T, 1994 (49)
Study site London (England)
Study population Heroin injectors attending DDCs in London in 1969 (see ref N 10)
N° of subjects 128
Follow-up period 1969-1991
Findings 43 (38% of those traced) died. Cause of deaths : 28 (68%) primarily associated with drug abuse; in particular 18
overdose and 10 other drug-related. 13 (32%) not primarily associated with drug abuse; in particular 2 suicides, 3
accidents 7 natural and 1 homicide.
Mortality rates=1.83%. Excess mortality ratio=11.9. The highest mortality rate was in the period 1983-1988
(2.64%), while the lowest was in the two period 1971-76 and 1977-82 (1.55%).
Comments Excess mortality rate = observed number / number expected to die  in an age and sex-matched sample of the
general population in a similar period.
LONGITUDINAL studies
Authors and year
(ref. N)
Zaccarelli M, Gattari P, Rezza G, Conti S, Spizzichino L, Vlahov D, Ippolito G, Lelli V, Valenzi C, 1994 (50)
Study site Rome (Italy)
Study population IDUs attending 2 Drug Centres in Rome who underwent HIV testing between 1985 and 1991.
N° of subjects 2431 IDUs: 770 (31.7%) were HIV -seropositive at enrolment; 1661 (68.3%) were HIV -seronegative, 82 of whom seroconverted during
the study period
Follow-up period 1985-1991
Findings 181 deaths: 89 due to AIDS, 43 to overdose and 49 to other causes. Total mortality rate increased over the study period from 1 death
(0.8%) in 1985 to 42 (3.6%) in 1991. The rate of death due to AIDS increased from 0.4 to 1.8% and death due to overdose from 0 to 0.5%
in the same period. Among men, the mortality rate was significantly higher for HIV+ than HIV- IDUs (Estimated Relative Risk 5.1) The
difference remained statistically significant (ERR 1.6), even after excluding deaths from AIDS. Among women, the excess of mortality was
also statistically significant both including and excluding AIDS deaths (ERR 7.8 and ERR 4.7 respectively).
The excess of mortality among the IDUs population was the following : SMR =34.9 in males and 24.2 in females. HIV+ IDUs showed
an excess for death due to overdose and to cardiovascular disease.
There was no difference in the rate of deaths due to pneumonia by HIV serostatus.
Survival analysis showed  a proportion of survivors =0.975 for HIV-, 0.927 for seroconverters and 0.825 for HIV+ (significant difference).
In the multivariate analysis HIV+ had a 4.5 greater risk of dying than HIV - IDUs, and the risk and a 6% increase for every year of age.
Comments The covariates used in the multivariate analysis were HIV status, age and sex.
Limitations with respect to selection of study participants: IDUs were recruited from drug-treatment centres only (duration of infection
is unknown); age was missing for nearly 20% of the participants (caution in interpreting results concerning the effects of age on mortality);
no information on behaviour and drug-treatment history was available; with regard to the SMR, these were calculated on a selected 
population of IDU undergoing HIV serological testing in two drug-treatment centres.
LONGITUDINAL studies
Authors and year (ref.
N)
Robertson JR, Ronald PJM, Raab GM, Ross AJ, Parpia T, 1994 (51)
Study site Edinburgh (Scotland)
Study population IVDUs participating to the Edinburgh drug addiction study, recruited following a consultation with a medical doctor
of the Muirhouse
Medical Group between 1982 and 1985.
N° of subjects 203
Follow-up period Follow-up conducted between January 1990 and June 1993.
Findings From the start of follow-up in 1990, 163 (91%) of the 180 survivors (23 subjects died before 1990) were traced, of
whom 116 (71%) were interviewed. Dramatic changes had occurred in drug taking, with a move away from
injecting towards oral drug use. A few patients continued to inject. 90 (78%) of those interviewed had been in
prison, of whom 37 (41%) had injected drugs while in prison.
There were 40 deaths (from 1983 to the end of 1992): 15 were attributed to overdose and 16 were AIDS related
deaths, 10 of which occurred in 1991.
Comments Mortality rate and Person-years at risk were not calculated. 
LONGITUDINAL studies
Authors and year
(ref. N)
Galli M, Mussicco M, 1994 (53)
Study site Milan (Italy)
Study population IVDUs voluntarily attending 4 public drug dependence treatment centres in Milan Metropolitan Area (MMA) between 01.01.80 and 
and 31.12. 88, that could be traced in the registry offices of the municipalities of MMA since 1981.
N° of subjects 2432
Follow-up period Follow-up was closed on June 1991.
Findings At the end of follow-up the cohort accounted for 16415 PY of observation. 413 deaths were registered (16%). The overall mortality rate
was equal to 25.2 per 1000 PY. The main causes of death were: 151 overdose (36.6%), death rate=9.2 per 1000 PY; 144 AIDS
(34.9%), death rate=8.8 per 1000 PY; 11 infectious disease (2.7%), death rate=0.7 per 1000 PY. Mortality remained under 16 per 1000
PY from1981 to 1986, then increased rapidly to 63.8 per 1000 PY in the first half of 1991. AIDS and overdose accounted for most of
this increase, with AIDS becoming the leading cause of death from 1989.
Compared to the Milan overall mortality rate, the age, calendar year and sex-adjusted SMR of the IVDUs cohort was=20.5.
HIV+ individuals showed a significantly higher overall mortality (48.0 per 1000 PY) than those with  unknown serological status
(19.9 per 1000 PY), due almost entirely to AIDS. HIV-1 infection does not appear to affect the mortality for causes other than AIDS and
infectious diseases.
Comments Expected deaths=specific mortality rates for the general population of Milan of the same age and sex.
Limitation of the study: some individuals with unknown HIV-status were actually infected, probably leading to an underestimate of HIV
prevalence and a lower difference between the two groups. Selection bias, since the cohort is hospital-based: patients who refer to the
hospital may have more advanced disease.
LONGITUDINAL studies
Authors and year (ref.
N)
Goedert JJ, Pizza G, Gritti F, Costigliola P, Boschini A, Bini A, Lazzari C, Palareti A, 1995 (59)
Study site Italy (Bologna and province and S. Patrignano Therapeutic Community)
Study population Drug users who was enrolled at least once on a treatment program between 1.1.80 and 2.7.90 + drug users seen
at the medical service of
the regional jail and at 2 hospitals in Bologna (infectious diseases clinics and wards)
N° of subjects 4962
Follow-up period January 1980 - November 1990
Findings 332 deaths. Mortality rate=1.57 per 100 PY, was 18-fold higher than that reported for adults in the city of Bologna.
Mortality rate was highest for HIV+  (2.6 per 100 PY) compared to untested (1.34%) and HIV - (0.28%). The
highest mortality rate by HIV status, sex and age-group was found in HIV+ men aged 30-63, the lowest in HIV -
women. Causes of death: 51 unknown, AIDS :150, overdose: 64, cyrrhosis: 25, other bacterial infection: 14. Both
AIDS and non-AIDS unadjusted mortality-rates increased with age.
Mortality due to bacterial pneumonia, tuberculosis, other bacterial infections, and hepatic diseases, but not non-
AIDS cancers, is increased with HIV-1 infection.
Comments Person-Years at risk were calculated from the earliest enrolment date (1.1.80) to date of death or latest available
date from any source if not known to be dead. Mortality rates  for age, sex and HIV status strata were estimated by
the Kaplan Meier method.
LONGITUDINAL studies
Authors and year (ref.
N)
Fugelstad A, Rajs J, Bottiger M, Gerhardsson de Verdier M, 1995 (61)
Study site Stockolm (Sweden)
Study population All known HIV+ IDUs in the Stockolm area during 1986-90 reported to the National Epidemiological Centre attending
MMTP or not.
N° of subjects 472 (135 participated in Methadone Maintenance Programme)
Follow-up period 1986-1990
Findings 69 deaths. A majority, 52 subjects, died as the result of violence or poisoning (41 deaths were related to injection of
heroin, 9 were attributed to suicide). Seventeen people died from somatic consequences of drug and alcohol abuse
(among these 9 died from AIDS).
The incidence rate for all causes of death was 3.3/100 PY for IDUs in the MMTP, 3.7/100 PY for those never in the
programme and  11.1/100 PY for those discharged from the programme. The latter had a RR of dying compared to
the IDUs never included in the programme =3.0. The incidence rate for cause of death related to violence or
poisoning was 0.8/100 PY for IDU s in  the MMTP, 3.1/100 PY for  those never in the programme and 8.9/100 PY
for those discharged.
The RR of the IDUs in the MMTP and of the discharged were respectively 0.3 and 2.9.
Comments Person-Years were calculated for different age group, knowing the date of birth and the date of first positive test.
The HIV+ IDUs population in Stockholm is well represented. The groups of IDUs Methadone Treatment and those
discharged are small, so that RR Confidence Intervals are wide. The decreased risk observed could be biased by
the exclusion from the programme of the cases with a higher mortality rate.
LONGITUDINAL studies
Authors and year (ref.
N)
Mc Anulty JM, Tesselaar H, Fleming DW, 1995 (62)
Study site USA (Portland,Oregon)
Study population IDUs not currently (within last 30 days) enrolled in any treatment programme, recruited through outreach workers
and public clinics
between April 1989 and March 1991.
N° of subjects 1769
Follow-up period April 1989 - December 1991
Findings 33 deaths, resulting in a crude death rate of 1048 per 100,000 PY. The age-adjusted RR of death was =8.3,
compared to the Oregon population. Causes of death: 13 overdoses (39%), 5 trauma (15%), 4 infections (12%)
Comments Impossible to identify predictive factors of premature death, because of the small number of deaths.  Difficulty to
find out-of-state deaths  (only matching with death certificates): the mortality rate for the cohort of out-of-treatment
injection drug users is at least as high as that for injection drug users enrolled in treatment, and may be an
underestimate.
LONGITUDINAL studies
Authors and year (ref.
N)
Friedman LN, Williams MT, Singh TP, Friedman TR, 1996 (63)
Study site USA (New York City)
Study population Welfare clients (18-64 years) who were given an examination to assess employability on 10 preselected days in
the third quarters of 1984, with a history of alcoholism (average daily consumption of 2 oz for at least 1 month)
and/or drug abuse (unprescribed injection  of any drug at any time or daily use of any orally or nasally narcotic for
at least 1 month)
N° of subjects 858
Follow-up period 1984-1992
Findings 183 deaths (21.3%), with a death rate of 2842 per 100,000 PY, 5.2 times the age-matched general population. The
main causes of death were: 66 AIDS (36.1%), 11 tuberculosis (6.0%), 18 infectious disease (9.8%), 16 cirrhosis
(8.7%), 8 overdose (4.4%) , 7 cardiac diseases(3.8%). Abusers of both drugs and alcohol were at significantly
higher risk of dying  (adjusted RR: 1.7).
Comments The study is part of a cross-sectional study on incidence of tuberculosis, from which 100 subjects with unknown
date of birth, 10 with active tuberculosis and 2 with an AIDS diagnosis before the beginning of the study have been
excluded.
LONGITUDINAL studies
Authors and year
(ref. N)
van Haastrecht HJA, van Ameijden EJC, van den Hoek JAR, Mientjes GHC, Bax JS, Coutinho RA, 1996 (64)
Study site Amsterdam (The Netherlands)
Study population Injection and non injection drug users recruited through "low-threshold" methadone program and through a sexually transmitted  disease
clinic for drug-using prostitutes, from December 1985 until July 1, 1992 (with restriction to participants with Dutch nationality)
N° of subjects 632
Follow-up period Follow-up was closed on 01.02.1993.
Findings At study entry, 489 (77%) participants reported ever having injected drugs, while 20 more reported at a repeat visit that they had initiated
drug injection. At entry, 139 (28%) injection drug users were HIV+, while another 32 seroconverted in the course of repeat visits.
A total of '72 deaths among IDUs were recorded ( two deaths occurred among persons who started drug injection in the course of repeat
visits) and 5 among non IDUs. Causes of death in IDUs: 16 overdose (7.2 per 1000 PY), 12 AIDS (5.4 per 1000 PY), 10 suicide (4.5 per
1000 PY), 8 infections (3.6 per 1000 PY).  The crude overall mortality rates was 32.3/1000 PY in IDUs and 8.8/1000 PY in non IDUs, giving
a rate ratio of 3.65. Among IDUs, HIV+ had a 3.6 times higher mortality risk. In multivariate analyses, limited to injection drug users, a
positive HIV serostatus, age above 40 years, and using benzodiazepines several times daily were significantly associated with an elevate
risk of death both for death from all causes and for death preceding AIDS diagnosis. Only 38% of HIV-infected injection drug users who died
were diagnosed with AIDS.
Comments Vital status was ascertained for 593 (94%) subjects.
IDUs were defined as those who had ever injected drugs. Those who started injecting after the enrolment in the study changed their
status from non injecting to injecting. A bias could have been occurred in the follow-up, because some people couldn't be censored because
of having moved out of Amsterdam (sometimes, in fact, drug users who became ill tend to move).
LONGITUDINAL studies
Authors and year (ref. N) Ortì RM, Domingo-Salvany A, Munoz A, Macfarlane D, Suelves JM, Anto JM, 1996 (65)
Study site Catalonia (Spain)
Study population Opiates addicts gathered from data bases regarding emergency rooms (ER) and treatment centres (TC), resident in Catalonia and
aged 15-44, between 01.01.85 and 31.12.91. Record linkage was performed to obtain a cohort with unique individual data. Addicts were
categorised in 3 groups according to the source of entry with which they were registered (ER, TC or both).
N° of subjects 15711
Follow-up period Follow-up started at the age of 15 or at the age of first admission if age was greater than 15, and finished at the age of 45, age on 31.12.91,
age of death
Findings Men were mostly recruited through TC. Fatality rates were highest among patients with ER as the only source of entry, women had  lower
overall fatality rates and were younger than men. Mortality rates increased over the period from 13.8 to 34.8 per 1000 PY (the increase was
statistically significant in the periods 1987-88 and 1988-89). In the multivariate analysis (adjusted for age, gender, source of entry and length
of drug use) the risk increased significantly in men and for longer length of use.
The  principal causes of death were overdose or dependence  (10.9/1000 PY) , AIDS (10.8/1000 PY) and violence (3.7/1000 PY).
All these causes showed increasing rates during the period, but AIDS had a greater slope, being the most important cause since 1989.
Comments Person-years were calculated for each category defined by gender, source of entry and calendar year. People not detected as dead in the
Catalonia Mortality Registry (CMR) were considered alive at the end of the study period. Mortality in the CMR was coded using the ICD,
IX Revision
LONGITUDINAL studies
Ref. N Setting Ascertainment of vital status Ascertainment of causes of death
1 Inpatients YES: F-up project of the US Public Health Service, YES: all confirmed by death certificate
         current arrest records,          most of all confirmed by autopsy
         Social Security Records
3 Outpatients ??? YES: hospital notes, death certificates, coroners
4 Inpatients YES: Dangerous Drug Branch of the Home Office NO
9 Outpatients NO YES: Narcotic Addict Rehabilitation Branch of
         the National Institute of Mental Health
         the National Institute of Mental Health
10 Outpatients YES: DDCs records NO
12 Outpatients YES: DDCs registers, NHS central registers, YES: Clinical notes, death certificates,
           hospitals, voluntary agencies, relatives,          coroners' inquest
           prisons, Mental Health Index, hostels
13 Outpatients YES: clinic records, Home Office, coroners' report
            hospital and physician records NO
14 Outpatients YES YES: Food and Drug Administration
15 Outpatients YES: Home Office and DDCs NO
Ref. N Setting Ascertainment of vital status Ascertainment of causes of death
16 Inpatients?? YES: Clinic records, city directories, death YES: death certificates, Connecticut vital
         notices, ecological zoning maps          statistics
20 Methadone maintenance pr., YES: questionnaires, DARP treatment YES: death certificates, medical examiner reports
therapeutic communities,
outpatients drug-free treatm.,
outpatients detoxification pr.,
intake only
23 Outpatient care, YES: National Central Bureau of Statistics YES: National Central Bureau of Statistics
inpatient psychiatric care,
drug rehabilitation home
social welfare files
students, military conscripts
24 Inpatients-outpatients YES: interviews and official sources: YES
         Central Population Registry, Institute for
         Psychiatric Demography, Central Police
         Registry, Drug Treatment Services
27 see Ref N. 20 see Ref N. 20 see Ref N. 20
29 Inpatients YES: Central and parish registers YES: Central Mortality Register (ICD-8)
31 Outpatients- Inpatients YES: Interview, Central Population Registry and YES: Death certificates
         Central Policy Registry
33 Outpatients YES: registries recording AIDS diagnoses and YES: hospital records, death certificates,
         death among patients of the program,          medical examiner reports
          hospitalizations
Ref. N Setting Ascertainment of vital status Ascertainment of causes of death
34 Outpatients YES: National Mortality Register YES: autopsy reports
36 Inpatient (care register) YES: National Cause Death Register YES: National Cause Death Register
37 Outpatients YES: Registry Office of the last municipality of YES: National Mortality files (ICD IX),
         residence          Registry Office of the municipality of death
39 Outpatients YES: MM programs, drug aids institutions, YES: hospital records, BDM registries,
         Registries of birth, death and Marriage (BDM)          post-mortem examination
40 Outpatients see Ref N. 37 see Ref N. 37
41 Outpatients YES: National AIDS registry,   YES: National Cause of Death Registry (ICD-9)
         Central Bureau of Statistics,
         National Cause of Death Registry
49 Outpatients YES: interview, clinical notes, Office of Population YES: death certificates from Home Office Index
         Census and Surveys, National Health Service
         Home Office Index
50 Outpatients YES: Register office of the municipality of last YES: death certificates + clinical records (ICD-9)
         residence
51 Outpatients YES: General Register Office YES: General Register Office
Ref. N Setting Ascertainment of vital status Ascertainment of causes of death
53 Outpatients YES: register office of the municipality of residence YES: death certificates, clinical records of the
         drug centres, (and, when available, hospital
         charts and autopsy reports)
59 Outpatients-Inpatients YES: local and national AIDS registries, vital YES: death certificates (ICD-9)
         statistics registries, compulsory registration
         list of the municipality
61 Outpatients YES: Methadone Maintenance Programme (MMTP) YES: autopsy reports, forensic chemical analysis,
         in Stockholm and Uppsala, Department of          police reports, hospital records
         Forensic Medicine, hospital records
62 Outpatients YES: ??? YES: death certificates
63 Outpatients YES: NYC tuberculosis registry, YES: Bureau of Vital records and death
         Vital records registry, AIDS registry          certificates
64 Outpatients YES: visit + interview or Register of population in YES: hospital records, coroners' office
         the town of residence
65 Outpatients-Inpatients YES: Catalonia Mortality Registry YES: Catalonia Mortality Registry (ICD-9)

REVIEW OF
CROSS-SECTIONAL STUDIES
CROSS-SECTIONAL studies
Authors and year (ref.
N)
Gardner R, 1970 (5)
Study site London
Source of data Home Office and Coroners' Registers (from the four Inner London Courts and all inquest cases in two of them)
Study period January 1965 to December 1968; incomplete data available for 1969 (from Home Office)
Number of deaths 112 + 58 in 1969
Findings All people "non-therapeutic" opioid users. 21% not previously known to the Home Office (1965-1968) (mean
age lesser than that of
addicts already registered). In the period 1965-1968: 72% of deaths from drug misuse - i.e. overdosage,
infection or treatment - 
excluding suicidal overdosage. 79% in 1969. 59 non-suicidal overdose in 1965-1968 and 38 in 1969. Most
misused drugs: heroin
and then barbiturates. Significant increase of deaths from methadone overdosage (suicidal or not): from 10% in
1965-67 to 50% in
1968. In the 1965-1968 series 55 died shortly after a period of opioid abstinence
Comments Some criticism as regard the use of Home Office List to calculate mortality rates among heroin users (the
addicts listed in the Home
Office Index are only a subgroups).
CROSS-SECTIONAL studies
Authors and year (ref.
N)
Sapira J D, Ball J C, Penn H, 1970 (6)
Study site Lexington,  Kentucky  (USA)
Source of data Lexington Hospital (clinical records, autopsy reports)
Study period From May 29, 1935 to December 31, 1966
Number of deaths 385  (90% males) among narcotics addicts hospitalized
Findings 25 non-natural deaths defined as violent (suicide, homicide and traumatic accident) or drug related. Causes of
deaths: 33.2% infectious; 22.3% circulatory diseases; 17.7% neoplastic process; 11.4% metabolic deaths. 9
deaths directly related to drug abuse(2.3%) and 16 (4.1%) violent deaths.
Comments Analysis of mortality not only from acute causes but also from chronic diseases. The study population includes
addicts from throughout the United States; no selection by race, sex or ethnic group  as admissions to the
hospital over the 31 years considered have reflected the demographic changes among addicts in general.
CROSS-SECTIONAL studies
Authors and year (ref.
N)
Cherubin C, McCusker J, Baden M, Kavaler F, Amsel Z,  1972 (7)
Study site New York (USA)
Source of data Narcotic Register of the New York Health Department and Office of the Chief Medical Examiner
Study period 1950 - 1970 and 1967
Number of deaths From 50 in 1950 to 1200 in 1970; in the second part of the study 591 deaths in 1967 were considered
Findings Increase of the annual number of deaths from use of narcotics (from 1950 to 1970). The marked increase from
1967 to 1970 was paralleled by a large increase in reports of addicts to the Narcotic Register.  Mortality rates:
1.28% in 1964, fairly constant from 1965 to 1968 (about 0.7%). 78% of deaths in 1967 due to "narcotism" (as
reported in death certificate). In 90% of these deaths evidence of recent intravenous injection. "Narcotism"
deaths strictly resemble for demographic characteristics the Register population and this would suggest that
there is no especially high risk group among addicts for this cause of death.
Comments Definition of "addict" specified: "person recognized as current illicit users by the source of data used".
Description of the characteristics of sources of data. Denominator of mortality rates: n° of addicts known to the
Narcotic Register at the middle of each year; numerator: addicts died already known to the Register.
CROSS-SECTIONAL studies
Authors and year (ref.
N)
Ghodse A H, Sheehan M, Stevens B, Taylor C, Edwards G,  1978 (11)
Study site Greater London
Source of data Eight Coroners' Courts
Study period From January 1970 to December 1974
Number of deaths 134 + 14 (10% random sample ) addicts whose cause of death not apparently directly related to their addiction.
Estimated addicts died during the five years: 274+/- 75 (95% C I for Poisson sampling)
Findings 78% of the main sample were males; 75% under 30 and 41% unknown to the Home Office. 53% of deaths
attributable to barbiturates overdose (in 62% of these cases addicts were known to the H.O). 15% deaths from
opiates other than methadone.
Comments Case definition: "death due to addiction" notified to coroners (regardless of the cause of death recorded and
category of drugs).
Description of characteristics and limits of the Home Office Index. Some criticism as regard the possibility of
Home Office to reflect the prevalence of all serious form of addiction.
CROSS-SECTIONAL studies
Authors and year
(ref. N)
Zimney E L, Luke J L,  1981 (17)
Study site District of Columbia (USA)
Source of data District of Columbia Medical Examiner's Office; Regional Laboratory of the Drug Enforcement Administration (for the
analysis on street heroin samples)
Study period July 1971 - December 1979
Number of deaths 287 deaths directly related to narcotic abuse
Findings 193 deaths (67.2%) due to heroin, 64 (22.3%) to methadone, 21 (7.3%) to heroin+methadone. Mean age 26.8 years;
83% males. Marked geographic clustering of deaths within the principal narcotic usage area of the city. 142 (49%)
known as chronic users (opiate tolerance at the time of death). Evidence of conjoint use of alcohol in 37% of the
deaths from heroin. During the study period variations in number of deaths and in type of drug identified. Free
morphine was identified more often in the blood of victims dying rapidly than in the blood of those with longer post-
injection survival. Significant correlation between number of heroin-related fatalities and the purity of heroin available
Comments Narcotic related deaths separated in two categories depending on the circumstances of death. The study group
consists of deaths directly related to the use of narcotic drugs (excluding fatalities from medical complications of
narcotic usage and unnatural causes in narcotic users).
CROSS-SECTIONAL studies
Authors and year (ref.
N)
Kringsholm B, Voigt J, dalgaard J B, Simonsen J,  1981 (18)
Study site Denmark
Source of data Three Danish University Institutes of Forensic Medicine (police reports, death certificates, autopsy report and
hospital records)
Study period 1978 - 1979
Number of deaths 215 (94 in 1978 and 121 in 1979)
Findings 79% males; mean age in both men and females 26 years, 41% unemployed. 74 heroin users. In most cases (112 -
-> 52%) a mixed abuse was present (stated as "abuse of hard narcotics" or "any drug available"), the predominant
drug being heroin.  In 62% of all cases the manner of death classified as an accident. 58% in treatment just before
death.
Comments Cases classified on the basis of the cause of death: 1) poisoning by one or more drugs or complications to this; 2)
narcomania as a contributory factor. No differences between the two groups (for sex, age and residence
distribution as well as anamnestic information)
CROSS-SECTIONAL studies
Authors and year (ref.
N)
Harvey J G,  1981 (19)
Study site London (four Inner London boroughs)
Source of data Coroner's inquest data
Study period 1979 - 1971
Number of deaths 175
Findings The number of male addict deaths was almost three times that of females. 88% of addicts who died were under
the age of 35  years and about 50% were not known to the Home Office. 80% of deaths associated with the
effects of drugs either directly (overdose 72%) or indirectly. Barbiturates involved in 59% of all cases of overdose,
strong analgesics in about 42%. Deaths indirectly caused by drugs (septicaemia, endocarditis and hepatitis) were
4.2% of all those attributed to drugs.
Comments Included all unnatural and violent deaths where a person was reported to be an addict or dependent on drugs or
other substances.
Difficulties in using coroners' inquest data in identifying deaths of addicts are explained.
CROSS-SECTIONAL studies
Authors and
year (ref. N)
Samkoff J S, Baker S P,  1982 (21)
Study site United States
Source of data National Centre for Health Statistics (NCHS)
Study period 1970 - 1978
Number of
deaths
67851 deaths ascribed to poisoning by drugs and medicaments. 22826 (34%) classified as unintentional (E-850-859)
drug poisonings were further analysed.
Findings 34% unintentional (E 850-859); 41% suicide (E950.0-3); 12% undetermined intent (E980.0-3); 13% drug dependence
(304). 
Results of analysis of mortality for unintentional drug poisonings: mortality rates per million population declined between
1975 and  1978 from 14.7 to 8.8 (40%). 73% of this drop attributable to a reduction in deaths coded to opiates (E853.0)
and intravenous narcotism (E854.8). Death rate for men was twice the rate for females. Mortality rates were especially
higher for ages 20-29, for males and for non-white. Time trends in mortality from opiate poisoning appear to coincide with
variations in the amount of heroin smuggled into the country.
Comments ICD VIII codes on the basis of deaths certificates information obtained from the states. Problems in analysis of vital
statistics data for drug related deaths. Whether a heroin overdose is coded as "accidental" ,"undetermined" or "natural
death due to drug dependence", depends on the information available to the medical examiner or coroner and the data
recorded on death certificate. The authors point out that deaths coded as "drug deaths undetermined", and "drug
dependence" peak in 1971 and 1975, showing the same pattern as deaths attributed to unintentional poisoning.
CROSS-SECTIONAL studies
Authors and year (ref.
N)
Spear H B,  1982 (22)
Study site United Kingdom
Source of data a) Home Office; b) H M Coroners; c) Office of Population Censuses (for England and Wales); d) Registral-General
(for Scotland)
Study period 1978 - 1980
Number of deaths 622 (1978: 192;  1979: 203;  1980: 227)
Findings 622 deaths associated with a "controlled drug " use (drugs included in the Schedule to the Misuse of Drugs
Regulations, 1973). 228 (36.6%) deaths previously unknown to the Home Office.
Overall rise (18%) in the total number of deaths in the three years period mainly due to increase in the group
previously unknown to the Home Office.
Overdose of various drugs main cause of death in the "known" addict group (58%). Much higher proportion of
overdoses in the "unknown" group. Higher involvement of opioids among the "unknown" addicts deaths. Higher
proportion of overdoses from barbiturates in the group of addicts "known" to the Home Office.
Comments The characteristics of the sources used and their limits in describing addicts mortality are specified.
Differences between the two group studied due to the methods used  to identify the "cases".
CROSS-SECTIONAL studies
Authors and year (ref.
N)
Ghodse G, Sheehan M, Taylor C, Edwards G,  1985 (26)
Study site United Kingdom
Source of data Home Office
Study period 1967 - 1981
Number of deaths 1499 (1273 - 85%- among "non-therapeutic" addicts)
Findings Ratio men:women 3.5:1. Over half of "therapeutic addicts" aged 50 or more. 60% of "non-therapeutic" addicts
aged 20-29. Drugs caused or were implicated in the deaths of 939 (74%) of "non-therapeutic" addicts, but the drug
was identified in only 745 deaths: 7% heroin; 30.5% barbiturates (in the early and mid-1970s); 15% other opiates
(10.6% during the last five years) and 11% methadone.
Crude mortality rates from 23.5/1000/year for the period 1968-1970 to 18.4/1000/year for the period 1978-1980
Comments Crude mortalities calculated by relating the number of deaths of addicts notified to the Home Office to the total
years of notification (year
at risk). Information only refer to addicts known to the Home Office (it is not necessarily applicable to others) and
this limit is specified.
All notified addicts who died from 1967 to 1981 were included whatever the cause of their death. Discrepancy
between the number of
deaths of addicts shown by the search of the index of deaths and the number reported in official Home Office
statistics
CROSS-SECTIONAL studies
Authors and year (ref.
N)
Kringsholm B,  1989 (30)
Study site Denmark
Source of data Three University Institutes of Forensic Medicine
Study period 1968 - 1986
Number of deaths 1618
Findings Deaths classified in two groups according to the cause of death: a) poisoning by drugs or complications due to this
(82%); b) drug abuse as contributory factor to this. No differences between the two groups regarding demographic
data and  anamnestic information (combined for the analysis). Number of deaths increases until 1980 (from 5 to
163). Males:females ratio 1:4 in each year. Average age from22/23 years in the early 1970s to 31 years in 1986.
Morphine abused in the whole period. Amphetamines abused in the first years and again in 1986. The percentage
of deaths among addicts with an abuse more than 10 years gradually increases throughout the period.
In the group a) morphine/heroin predominant drug of poisoning (30-50%). Few  cases of cocaine poisoning.
Comments Causes of death classified on the basis of information from: police reports, death certificates, autopsy reports and
hospital records if any.
No ICD coded specified. Medico-legal autopsy performed in 97% of cases and toxicological analysis in 94% of
deaths in the group a).
CROSS-SECTIONAL studies
Authors and year (ref.
N)
Klatt E C, Mills N Z, Noguchi T T,  1990 (35)
Study site County of Los Angeles
Source of data Files of the Autopsy Department of the Los Angeles County-University of South California Medical Centre
Study period 1981 - June 1989
Number of deaths 274 deaths with autopsy evidence of intravenous drug use (patients admitted to a large, acute-care public hospital)
Findings Mean age 39 years; 214 (78%) males. 127 (46%) deaths unrelated to intravenous drug abuse. The commonest
diseases in this group: alcoholism (415), cardiovascular diseases (17%), infections (15%), malignant neoplasm
(14%) and accidents (9%). In 147 patients (54%), death was related to intravenous drug abuse, the causes
included AIDS (49%), infective endocarditis (19%), overdose syndromes (14%).
Comments Findings markedly different from reports of deaths in non-hospitalized intravenous drug abusers (including deaths
reported to the medical examiner, persons registered as addicts by governmental agencies and military
personnel). Different impact upon mortality statistics according to the different kind of study population. Persons
hospitalized with a history of intravenous drug abuse die from other causes than overdose (AIDS and chronic
alcoholism). Necessity to detect "hidden" intravenous drug deaths to provide more accurate statistical information
CROSS-SECTIONAL studies
Authors and year (ref.
N)
Frischer M, Bloor M, Goldberg D, Clark J, Green S, McKeganey N,  1993 (44)
Study site Glasgow
Source of data Three independent agencies: 1) Procurator Fiscal's Office; 2) General Register Office; 3) Scottish HIV-test
Register
Study period 1989
Number of deaths 51 individuals  (corresponding to 81 deaths recorded by the three different sources)    -    Estimated population of
drug injectors: 9424
Findings Mortality rate 0.545 in the estimated population (rate for females: 0.85%; for males: 0.42%). Over 90% of deaths
attributed to overdose or suicide. 19% HIV+, AIDS caused only 1 death. Mortality rates among HIV+ injectors
significantly higher than among HIV- injectors.
Male and female injectors respectively 1.5 and 4 times more likely to die than general population of the same sex
and age.
Comments Mortality rates calculated using as denominator the estimated population of drug injectors. The observed mortality
rate was lower than in previous studies where the denominators use to calculate rates had an element of
underenumeration. The authors point out that ICD currently used to classify drug-related deaths are not precise to
discriminate codes injectors from non-injectors. Moreover each drug involved in deaths from overdose should have
a separate code
CROSS-SECTIONAL studies
Authors and year (ref.
N)
Wysowski D K, Schober S E, Wise R P, Kopstein A,  1993 (47)
Study site United States
Source of data National Centre for Health Statistics
Study period 1979 - 1988
Number of deaths Deaths attributed to misuse of psychoactive drugs classified as: a) drug-induced (drugs implicated as the
underlying cause); b) drug-related (drugs implicated as the underlying or contributing cause- multiple cause). Total
number not specified
Findings A 1.3 fold increase (from 6.5 to 10.0) of psychoactive drug-induced deaths based on underlying cause, due
primarily to death codified as accidental poisoning by drugs. a 1.5 fold increase for unspecified category 304.9.
Annual rates higher for males than for females. A 1.7 fold increase (from 7206 to 14408) of psychoactive drug-
related deaths based on counts of underlying or contributing cause. a 7.4 fold increase for non-dependent abuse
category and 3 fold increase for drug-dependence category (-->largely due to its being listed as a contributing
cause in death from AIDS).
Comments Methods and criteria used for describing mortality attributed to misuse of psychoactive drugs specified. ICD IX
reviewed to select codes for deaths from misuse or abuse of psychoactive drugs
CROSS-SECTIONAL studies
Authors and year (ref.
N)
Kaa E, Teige B,  1993 (48)
Study site Aarhus (Denmark) and Oslo (Norway)
Source of data Institutes of Forensic Medicine
Study period 1980 - 1989
Number of deaths Fatal poisoning among drug addicts: 238 in Aarhus; 263 in Oslo
Findings In both samples 80% were males. Increase of annual number of deaths among drug addicts in age groups over 30
years. Only in the Norwegian sample, the increase in the annual number of deaths due to an increase of
heroin/morphine related deaths. 48% of deaths in Danish sample due to registered medical drugs (methadone,
propoxyphene)
Comments The definition of "drug addict" applied is specified. The use of the same selection criteria and definition of case in
both samples allows for making comparisons. This study does not include all drug-related deaths among drug
addicts but only poisoning cases.
CROSS-SECTIONAL studies
Authors and year (ref.
N)
Risser D, Schneider B,  1994 (52)
Study site Vienna
Source of data Institute of Forensic Medicine
Study period 1985 - 1992
Number of deaths 372 drug-related deaths (including: a) narcotic overdoses; b) deaths due to long-term effects of drug abuse; c)
suicidal related to drug abuse; d) violent deaths under the influence of drugs; e) medication overdoses; f) deaths of
persons registered as drug users)
Findings Statistically significant increase in drug-related deaths over the years. 68% of deaths due to narcotic overdose;
16% due to medication overdose (illicit use of medication as a drug substitute). Among 230 deceased individuals
(categorized as drug injectors) 17.4% HIV+.
Morphine and barbiturates detected respectively in 76% and 24% of cases. In 58% of deaths more than one drug
was detected
Comments No ICD codes specified. Drug-related deaths classified according to the definition issued by the Austrian Ministry
of Internal Affairs.
Definition of drug-related death (in particular in those cases in which death was not connected with actual drug
intake) not entirely satisfactory --> possibility of some cases overlooked.
CROSS-SECTIONAL studies
Authors and
year (ref. N)
de la Fuente L, Barrio G, Vicente J, Bravo M J, Santacreu J, 1995 (57)
Study site Madrid
Source of data National Institute of Statistics (for all causes mortality); AIDS Registry (for AIDS deaths related to drug injection); State
Information System on Drug Abuse ("mortality indicator") and previous retrospective studies (for acute drug reactions)
Study period 1983-1990
Number of
deaths
Estimated rates x 100000 population for each year.
Findings All of the mortality rates increased from 1983 to 1990 with differences between sex: all causes from 101/100000 to
148/100000,
acute drug reactions from 3/100000 to 15/100000 and AIDS from 0 to 20/100000. Drug-related mortality represented
60% of the
increase in the rate from all causes in males and 170% of the increase in females
Comments Four groups of causes of death were considered: all causes, AIDS in injectors, acute drug reactions and drug-related
deaths (defined as the sum of deaths from acute drug reactions and AIDS deaths).
Mortality rates calculated using as a denominator projection based on the 1981 census and 1991 census. Suicides,
acute reactions to drugs other than opiates and cocaine and indirectly related deaths consumption (violent deaths,
accident, infections) not included.
The characteristics of the sources of data used are described.
CROSS-SECTIONAL studies
Authors and year
(ref. N)
Sanchez J, Rodriguez B, de la Fuente L, Barrio G, Vicente J, Roca J, Royuela L, and the State Information
System on Drug Abuse (SEIT) Working Group, 1995 (58)
Study site Six major Spanish cities: Madrid, Barcelona, Valencia, Seville, Zaragoza and Bilbao
Source of data SEIT ("mortality indicator"), pathologists' report of each city's Institute of Anatomy and Pathology (IAF)
Study period 1983 - 1991
Number of deaths A total of 2596 in the six cities (49,6% in Madrid and 28,5% in Barcelona)
Findings Increase of the number of deaths between 1983 and 1991(5.6 times among women and 7.3 times among men). The
largest absolute increase (rates differences) in Madrid and Barcelona. Male/female ratio 5.9:1. Mean age of
deceased from 25.1 in 1983 to 28 years in 1991. Toxicological tests for 53 % of total deaths: opiates found in more
than 90% of cases (in 34.3% as a single drug); cocaine almost always in conjunction with opiates (cocaine alone in
0.7% of cases). Increase of polyconsumption throughout the period(heroin/morphine+ benzodiazepines)
Comments Criteria for case selection and sources of information are described.
Deaths from acute reactions to opiates or cocaine defined according two criteria: a) lack of evidence of another
cause of death;
b) existence of some indication or evidence of recent consumption of opiates or cocaine. Denominators for mortality
rates obtained from official census data. The numerators refer to "deaths occurred in" the territory of a city (whether
or not the person reside in the territory) while the denominators refer to "person resident in that city". Possible
sources of error are specified (errors in identification of cases and the atypical nature of the rates calculated): the
result could be a slight overestimation of the mortality.
CROSS-SECTIONAL studies
Authors and year
(ref. N)
Hammersley R, Cassidy M T, Oliver J, 1995 (60)
Study site Glasgow and Edinburgh
Source of data Death reports (not specified). For toxicological analysis: the Department of Forensic medicine and Science
Laboratory
(for Glasgow) and the Police Forensic Laboratory (for Edinburgh)
Study period November 1990 - October 1992. Two time periods were compared: November 1990-1991 and November 1991-1992
Number of deaths 66 in Glasgow and 26 in Edinburgh
Findings The increase in deaths in Glasgow was significant.
large number of deaths in Glasgow but were rare in Edinburgh where methadone was associated with most of
deaths.
Temazepam, diazepam and alcohol associated with most deaths in Glasgow.
Comments Categories of death included: all sudden and unexpected deaths where the circumstances of death suggested drug
injection Drug-related death defined as deaths where drugs were implicated as a cause of death either through
circumstance or toxicology. Deaths from infectious diseases and accidents excluded. No details on the
characteristics of people died (sex ratio, age distribution ..) are reported.
CROSS-SECTIONAL studies
Authors and year (ref.
N)
Torralba L, Brugal M T, Villalbi J R, Tortosa M T, Toribio A, Valverde J L,  1996 (66)
Study site Barcelona
Source of data Sistema d'Informacio de Drogues de Barcelona (SIDB)
Study period 1989 - 1993
Number of deaths 782 deaths from acute adverse drug reactions
Findings Deaths among city residents: 79.7%. Mortality rates higher for men than for women (25 per 100000 and 5.8 per
100000 respectively).
Mortality rates by age groups group show different pattern by gender. Wide differences between districts and
between neighbourhoods in mean annual rates. Although all areas with high adverse drug reactions mortality
are areas of low socio-economic level, other areas with similarly low socio-economic indicators do not suffer
such high mortality.
Comments Definition of "deaths due to acute adverse drug reactions (from heroin and/or cocaine)": deaths caused directly
by use of these substances (pharmacological overdoses, allergic reactions and toxic reactions to substances
added to drugs). Age  and sex specific death rates computed using as denominator data from 1991 municipal
census. Geographical analysis of mortality at small areas (level districts and neighbourhoods) wad carried out.
REVIEW OF CASE-CONTROL STUDIES
CASE-CONTROL studies
Authors and year
(ref. N)
Ruttenber AJ and Luke JL , 1984 (25)
Study site District of Columbia (USA)
Study period and 
source of data
Records about drug-associated deaths of the Medical Examiner's Office from 1 January 1976 through 31 December 1982
(endemic period: Jan 1976-Dec 1979; epidemic period: Jan 1980-Dec 1982).
Columbia Metropolitan Police Department analysed heroin purchased on the street.
Cases Heroin-related deaths (HRD): 1) deaths with a post-mortem toxicology positive for morphine but with no trauma or natural disease
contribution; 2) deaths occurred during hospitalization for effects of documented heroin administration.
Controls 1) General Control group (GC): all deaths due to natural or traumatic causes with either cutaneous stigmata of intravenous narcotic
use or positive blood morphine level;
2) Morphine-Positive Control group (MPC): member of the GC group with positive blood morphine levels and no measurable
level of any other narcotic drug.
Findings HRD increased between the second quarter of 1979  and the second quarter of 1982; the population-based mortality rate  in 1981
was 17.4 per 100,000 (possibly the highest ever reported).
Blood concentrations of both ethanol and heroin can be considered as risk factors for HRD. Moreover, the quantity of heroin in
packages sold in the street, its price and the quinine weight per package can be HRD predictors as well.
HRD seems to be associated with a casual or recreational use (they were significatively higher during the spring or summer, on
Friday or Saturday, from 6 p.m. through 12 p.m.; protective effects of concentrations of heroine in bile)
Comments Any  overdose deaths  with toxicological evidence of other narcotics alone or in combination with morphine was excluded in the
selection of cases. Comparison with the MPC group adjusts for the possibility that some controls were not active heroin users
at the time of death.
Analysis of data from autopsy and from street drug composition seems to be useful for identifying new patterns of drug abuse
and risk factors  for HRD, leading to the identification of prevention strategies.
CASE-CONTROL studies
Authors and year
(ref. N)
Davoli M, Perucci CA, Forastiere F, Doyle P, Rapiti E, Zaccarelli M, Abeni DD, 1993 (43)
Study site Rome (Italy)
Study period and 
source of data
A cohort enrolled for a longitudinal study from 3 Public Treatment Centres in the period 1980-1988 (see Ref. N. 37).
Cases Overdose deaths (81) among all the deaths in the cohort.
Controls 4 controls for each case (324) were selected among the cohort members still alive at the time of death of the corresponding case, 
matching on year of birth (+ 2 years) and sex.
The variables of interest were considered up to the time of death of the corresponding case.
Findings High risk of overdose death among subjects who left treatment compared with those still in treatment (OR= 3.55). The highest OR
was seen in the first 12 months after drop-out (OR= 7.98). The risk of overdose death was higher among the unmarried compared
to married subjects (OR= 2.48). There was a non statistically significant association with lower educational status and younger
age at first drug use.
Comments The selection of controls was made following the 'incidence density' or 'concurrent' sampling procedure, which allows an unbiased 
estimate of the rate ratio.
Exposure of interest were socio-demographic characteristics, pattern of drug use, pattern of treatment. Information on some of these
was derived from clinical records and had a limited validity that could account for the lack of association between overdose
death and these exposures.
A subject was considered retained in treatment when his last contact occurred within 30 days before the date of death or the
corresponding date for controls (probably another cut-off point should change the results).
It wasn't possible to investigate on concurrent effect of alcohol abuse (information not available), on recreational  use of drugs
(regular users population) and on comparison with drug users non in treatment (the population came from treatment centres) .

REVIEW OF LETTERS, REPORTS AND EDITORIALS
LETTERS
Authors and year (ref.
N)
Reig P, Sanz P, Martì G, Corbella J,  1987 (28)
Title Opioid-related deaths in Barcelona 1981 - 86
Summary Rapid increase in the number of deaths related to opioids overdose in Barcelona during 1981-86. In this six years
118 deaths (97 males and 21 females) related to possible opioid overdose were recorded in Barcelona. In the
same period registered deaths from various toxic substances totalled 354. Opioids were associated with 50% of all
the fatal poisonings in 1985 while in 1982 they came third in the list of leading causes of death by poisonings and
in 1981 sixth. This change is attributable both to an increase in the number of heroin addicts and to changes in the
purity of street heroin, which is influenced primarily by the drug's country of origin
LETTERS
Authors and year (ref.
N)
Woody G E, Metzger D S, 1993 (42)
Title Causes of death in injection-drug users
Summary In the midst of the AIDS epidemic injection-drug users continue to engage in risky behaviour that continues to
account for an unacceptably high rate of HIV infection.
In a previous longitudinal study the authors found among 415 injection drug-users enrolled, only 5 (18%) deaths
from causes associated with HIV disease, although 11 were HIV-positive. The other 82% died from drug-
overdoses, homicide, heart disease, renal failure, liver disease, suicide and cancer.
Given the immediate threats to their lives, injection-drug users may not share the sense of urgency about wearing
a condom, avoiding a used needle, or using proper needle-sterilization techniques: the threat of death from other
causes is more imminent. Although physiologic dependence, interpersonal expectations and emotional distress
may explain the intractability of risky behaviour among this population, they also highlight the success achieved by
those who have increased their use of safe behaviour despite discouraging circumstances
LETTERS
Authors and year (ref.
N)
Frischer M, Bloor M, Goldberg D, Clark J, Green S, McKeganey N,  1993 (45)
Title Mortality among drug injectors and notified addicts
Related paper Frischer et al. J Epidemiol Community Health, 1993 (see cross-sectional Ref N. 44)
Summary (see ref n. 44) and the number of deaths among drug addicts for the whole of  the UK (from 1956-66 and from
1976-81) reported by the Home Office Notification Index. Before September 1987 it was not ascertained whether
those who were notified injected drugs and, on reflection, it should be avoided making comparisons between the
two groups since the UK figures the author cited refer to deaths among notified non-therapeutic heroin addicts
which are probably not a good surrogate for mortality among injectors.
The methodology described  in their previous paper was an attempt to circumvent the limitations of reporting
mortality in selected groups of injectors, such as those reported to the HONI and enable straightforward
comparisons with the general population for a given year.
Considering that the average  annual number of all-cause deaths in the Glasgow population aged 15-34 years is
about 300, the finding of 45 deaths in drug injectors (see ref n. 44) indicates that injecting drug use is strongly
associated with an increased risk of mortality in young adults, and is probably responsible for more deaths among
this group in Glasgow than any other single factor
LETTERS
Authors and year (ref.
N)
Davoli M, Forastiere F, Abeni D D, Rapiti E, Perucci C A,  1994 (54)
Title Longitudinal and cross-sectional mortality studies in injecting drug-users
Related paper Frischer M et al, 1993 (see cross-sectional Ref N. 44)
Summary The authors refer to a paper of Frischer et al published in 1993 concerning mortality among drug-injectors, where
they reported a mortality from all causes of 54%: this estimate is considered lower than that reported in previous
studies (see ref n. 24, 27, 33, 36 and 37) . The main difference between these studies and that of Frischer et al is
that the former are all longitudinal flow-up studies, while the latter estimates numerator and denominator
separately. The lower rate shown in Frischer's study is not attributable to an underenumeration of the denominator
but to the estimate of numerator. In fact over 90% of deaths reported in that study were attributed to overdose and
suicide, 2% to AIDS and accidental causes and only 8% to other medical causes. The results from other studies
show that the proportion of deaths not directly related to drug use is relevant and injectors have an excess risk for
other causes of death. Such an excess risk could have been missed using the sources described by Frischer et al.
In conclusion, the only way to measure mortality from all causes in drug-injectors is to carry out longitudinal follow-
up studies of defined populations.
LETTERS
Authors and year (ref.
N)
Frischer M, Goldberg D, Green S, Bloor M, Clark J, McKeganey N,  1994 (55)
Related paper Letter of Davoli et al, 1994 (see letters Ref N. 54)
Summary Frischer et al in their replay point out (as done by Davoli et al) that intravenous drug users are a dynamic
population with some current users stopping drug use each year, but in the longitudinal study carried out by Davoli
et al no information was available about these changes. For this reason Frischer et al consider an alternative
method to estimate mortality among injectors using a cross-sectional design (see ref n 44). They found that only
34 of 51 deaths were directly attributable to drug use and the remaining 17 were due to other causes including
accidents, suicide by hanging and a variety of medical conditions. While the non-injecting related conditions
identified by Davoli et al accounted for 28% of deaths in the italian cohort compared with 10% in Glasgow
injectors, the reasons for excess mortality associated with these conditions among intravenous drug users are
multifactoril. Thus, there is no logical reason why the mortality for selected conditions in different settings and time
periods should be similar. Frischer et al think it extremely unlikely that more than a handful of current injectors who
died from medical conditions were not detected in their cross-sectional study. The authors do not accept that "the
only way to measure mortality from all causes in drug injectors is to undertake longitudinal follow-up studies of
definite populations" (as emphasized by Davoli et al).
Longitudinal and cross-sectional methods address related but not identical issues, the complexities of which await
further investigation.
LETTERS
Authors and year (ref.
N)
Marks J,  1994 (56)
Title Deaths from methadone and heroin
Summary The UK Home Office Statistical Bulletin reported from 1982 to 1991 243 heroin deaths and 349 methadone
deaths. Given that the estimated total addict population in the UK is at least 123500 and taking into account that
40% of notifications (24700 in total) are of addiction to methadone (n=9880), this leaves 113620  addicted to
heroin. In 1991, 44 heroin deaths out of 113620 addicts yield a mortality of 1 in 2582; 74 methadone deaths of
9880 give a mortality of 1 in 134. Thus methadone would appear to be 19 times more toxic than heroin. Police
surgeon in London find that prescribing of methadone syrup by London's doctors is ineffective in stopping illicit
drug use and, worse, the methadone is sold on. Furthermore, methadone produces disturbances of weight ,
sweating, sleep;  and disphoria, in addiction to greater number of fatalities. Given the dangers of methadone and
its apparent ineffectiveness, perhaps the current vogue for methadone in the management of addiction should be
reviewed
REPORTS
Authors and year
(ref. N)
Cherubin C E, 1967  (2)
Study site New York City
Source of data New York City Department of Health (Narcotics Registry Project) and Office of the Chief Medical Examiner
Study period 1950-1961; 1964
Number of deaths Number of deaths directly or indirectly attributable to narcotism: 465 for 1950 to 1954,611 for 1955 to 1959 and 1314 for 1960 to
1964 (361 deaths provisionally listed for 1964)
Findings The disease states associated with addiction to narcotics are reviewed.
During the years 1950 through 1961 48% of addict deaths attributed to an "acute reaction to dosage or overdosage". In 1964
this cause of death accounted for 317 of the 361 deaths (87%). 120 deaths were examined by the NY City Medical Examiner's
1950 to 1961 tetanus contributed 8.3% of the deaths of addicts seen by the Office of the Chief Medical Examiner. In this 12-years
period endocarditis and sepsis were the causes of death in 8.7% addicts deaths and 2.1% was attributed to tuberculosis.
High prevalence of abnormal liver function tests and histologic findings of "small foci of round cell infiltration, particularly in the
periportal areas".  There is not sufficient evidence to attribute this abnormalities to a viral hepatitis.
Glucose tolerance abnormalities and overt diabetes are seen frequently among hospitalized addicts.
Overall estimates of 700 to 1000 addicted mothers delivering each year are made by the NY City Department of Health. High
prevalence of toxaemia (36%) and of prematurity (47%) by weight.
Comments This review of conditions associated with narcotic addiction was undertaken to identify gaps of knowledge concerning medical
problems likely to arise in any large-scale addict rehabilitation program in a moment when clinical diseases of drug addicts were
receiving relatively scant notice
REPORTS
Authors and year
(ref. N)
Helpern M,  1972 (8)
Study site New York City
Source of data Not specified
Study period 1950 - 1970
Number of deaths 1076 from 1950 to 1959 and 4254 from 1960 to 1969
Findings The greatest number of narcotic deaths occurred in the Borough of Manhattan.
Steady increase in fatalities directly caused by narcotic addiction during the last 21 years through 1970. First striking increase in
in 1961 (311 deaths).  The total number of deaths from narcotism from 1950 through 1959 was 1076 (sex ratio males/females
3.5:1)
From 1960 through 1969 there were a total of 4254 deaths. During the 10 years from 1950 to 1959 about 75% of deaths were in
individuals under 35 years of age. The average mean age at death from narcotic addiction  over the 12 years span from 1950
through 1961 was 29 years; in 1969 was 25 years; in 1970 the greatest number of deaths - 275- was in the age group 20 through
24 and the next to the largest - 179- was in the group between 25 and 29. In 1970 80% of the deaths caused directly by narcotism
were from immediate acute reactions and the remaining 20% were caused by complications including sepsi, tetanus, hepatitis and
endocarditis.
Comments The report provides preliminary background information describing narcotic addiction in New York City over the last 40 years.
The number of deaths among addicts in NY City are reported from 1950 through 1971. The geographic distribution, characteristics
of place of death and pathologic findings are also described
REPORTS
Authors and year
(ref. N)
Jansenn W, Trubner K, Puschel K, 1989  (32)
Study site Hamburg and the Federal Republic of Germany (FRG)
Source of data Federal Criminal Police Office
Study period 1970-1988.
Number of deaths FRG: steady increase from 1970 through 1979 when 600 deaths were counted; afterwards, deaths decreased to 300-500 annually.
In Hamburg the situation was similar except for the last 2 years ('87-'88) when a great increase was observed (1987: 51 deaths,
Sep-1988: 50).
Findings IDUs estimated: 70000-80000. Sex distribution changed from 4.9:1 in 1975 to 2.6:1 in 1985. Mean age increased from 25 to 30.
Compared to the other European countries, FRG had the highest number of deaths in the years 1980-86 (400 yearly), followed by
Italy (300) and France (200).
Death rates varied widely between different region of FRG: the highest were in Hamburg, Bremen and Berlin.
In 1986 the mean time of survival was 8.1 years for male IDUs and 6.5 for female.
Investigations in Hamburg : almost 100% of dead IDUs underwent autopsy. Cause of death: 70% intoxication; 10% natural death;
20% external violence. 20% were HIV infected; anti-HBs-Ag was present in 42% of the cases.
The largest group of intoxications depends on heroin, followed by mixed intoxication (alcohol, barbiturates and benzodiazepine)
Comments Definition of a drug death (essential for nation-wide analyses): 1) death due to intentional or accidental overdose;
2) death due to long-term abuse of drugs; 3) suicides connected with dependence on drugs; 4) fatal accidents influenced by drugs.
The same or similar definition are found in Denmark, Ireland, Monaco and Norway.
The association between drug abuse and death is not determined according to the same standards anywhere in the FRG.
REPORTS
Authors and year
(ref. N)
Puschel K,  1993 (46)
Study site Hamburg (Germany)
Source of data Institutes of Legal Medicine
Data on HIV-1 prevalence of drug-related fatalities from a multicenter study involving the Institutes of Legal Medicine in the Federal
Republic of Germany
Study period Temporal trend of drug-related deaths in Hamburg showed for the period 1970 - 1991
From 1978  every case of drug-related deaths have been investigated microscopically and toxicologically 
Number of deaths Number of drug-related deaths (DD) reported only for 1990 (n=136) and 1991 (n=184)
Findings Intentional or accidental overdoses represent about 70-90% of all DD. Since 1988 the number of DD in Germany has
increased (1491 in 1990 and 2125 in 1991). The rate of DD per 100000 people differs widely in different regions: high mortality
rates can be found in Hamburg, Bremen and Berlin. In 70-80% of the drug victims inflammatory liver changes were found
(in 1991: about 35% of serogically investigated DD were HBV positive and about 50% were HCV positive). HIV-1 prevalence rate
in Hamburg is the lowest in Germany, less than 5% (the prevalence lies between 0% and 20%). The percentage of acute
intoxications by heroin in Hamburg has permanently increased (since 1988, 70-80% of DD due to intoxication with heroin). 
Combined intoxications with alcohol, barbiturates and benzodiazepines are common
Comments The definition of drug-related death is specified. Since 1979 drug-related deaths in Germany are registered according to the
following definitions: a) death due to intentional or accidental overdose; b) death due to long-term abuse of drugs, i.e. hepatitis,
AIDS myocarditis; c) suicides connected with dependence; or d) fatal accidents influenced by drugs
EDITORIALS
Authors and year
(ref. N)
Selwyn PA, 1991 (38)
Related paper Perucci et al. Am J Public Health, 1991 (see longitudinal studies Ref N. 37)
Introduction Increased risk of mortality and morbidity in injection drug users (IDUs) before and after AIDS epidemic. Since the AIDS-era, AIDS-
related death increased among IDUs, but overdose increased as well and remains a major cause of mortality. Moreover, drug
abuse effects on mortality seem to decline unless multiple causes are considered (standardization of collection, coding and
analysis of mortality data are needed).
Comments Perucci et al. showed, in a cohort of 4200 IDUs attending methadone treatment centers in Rome between 1980 and 1988, an
increase in overall and in AIDS mortality. SMR for endocarditis, neoplasm, pneumonia, hearth disease, suicide, cirrhosis also
increased.
Overdose remained the leading cause of death.
Italy and Spain have the highest number of AIDS cases among IDUs: in Southern Europe there was an increasing use of heroin in
the late1970s, years of the beginning of HIV introduction; this could led to a rapid HIV spread in the IDUs population.
Studies from USA and from Europe suggest that the full spectrum of HIV-related disease in drug users may be underestimated by
AIDS surveillance only, because of the increase of mortality from pneumonia, tuberculosis, sepsis, corresponding to high AIDS
incidence.
Moreover, Perucci et al. observed an increase in occurrence of neoplasms and other malignancies linked to HIV infection,
suggesting a role of HIV infection plus use of tobacco and alcohol as risk factors for development of cancer.
Existing data on a positive correlation between methadone and retention in treatment and between the latter and reduced risk of
health response to AIDS epidemic.
Standardized protocol to assess overall and cause specific mortality
rates among drug users recruited in treatment centres in the Member
States of the European Union
Introduction
The final task of the EMCDDA project, carried out by the Osservatorio Epidemiologico,
was  to develop a standardized methodology to assess overall and cause specific mortality rates
among drug users in the Member States of the European Union. In order to discuss the major issues
to be taken into account for drawing a common protocol to carry out a mortality study in different
countries, an expert meeting was organized identifying research groups with experience in planning
and conducting cohort studies.
All the Member States of the European Union were informed, through the National Focal
Points, about the project and were asked to nominate, if interested, a contact person with experience
in  this kind of study for attending the meeting. The expert seminar was held at the Osservatorio
Epidemiologico in Roma on the 5th and 6th of May 1997 (annex 1: list of participants).
During the seminar each participant  presented a brief overview of cohort mortality studies
that have been conducted in his country and provided information on availability of the sources  of
the ascertainment of vital status and causes of death and on accessibility to health records of drug
users. General information to evaluate the feasibility for a mortality cohort study and on the
characteristics of treatment programs in each country were also gathered through a specific
questionnaire (annex 2).
During the seminar the major issues to be addressed and clearly stated in developing a
standardized methodology, allowing for temporal and geographical comparisons, were discussed
on the basis of the guidelines previously prepared by the Osservatorio Epidemiologico. This protocol
was developed according to the suggestions derived from the discussion on each of the following
issues:
1. Definition of case
2. Cohort definition
3. Information to be collected
4. Follow-up procedures
5. Cause of death determination
6. Calculation of person-years at risk
7. Calculation of mortality rates
One topic of discussion during the expert meeting, was whether to recruit drug users only
in treatment centres or also outside treatment. Even though a conclusive decision was not reached,
the most feasible option appeared to be recruitment in treatment centres.
Another topic discussed in the meeting was the opportunity of including in the study only opiates
users or also consumers of other types of drugs.
The major issues are:
1) selection bias; if treatment centres are used as recruitment sites, which appears the most feasible
option, the following consideration should be kept in mind: at present most drug users entering
treatment in Europe are opiate users. Non opiate users (cocaine, amphetamines, cannabis, etc)
entering treatment represent a very selected group, and mortality figures derived from this sub-
population may be highly biased and non-representative of the source population.
2) power; in order to detect statistically significant geographical and temporal differences in
mortality rates among drug users, a minimum number of drug users should be enrolled in each
country. The available figures from characteristics of treatment demand in different European
countries, suggest that only opiate users might be considered for this purpose. A detailed
analysis of power calculation will be a task of the feasibility study.
Even though the final conclusion has been left to the results of the feasibility study, the
following draft protocol deals with the apparently most feasible option of enrolling a cohort of
opiate users "attending" treatment centres.
1. Objectives
a. To estimate overall and cause-specific mortality among opiates users recruited in       
treatment centres
b. To analyze temporal trends in overall and cause specific mortality
c. To compare mortality of opiates users among countries
2. Definition of cohort
Both a retrospective and  prospective cohort study will be carried out. The study population
will include "incident" and "prevalent" individuals with respect to treatment, enrolled and followed
up at variable points in time (dynamic cohort). Incident subjects are those starting treatment for the
first time or starting a new treatment; prevalent individuals are those already in treatment at the
moment of enrollment.
3. Study population
The study population will consist of a cohort of opiates users  (by injection or other routes
of administration) who start *  treatment at a treatment centre at least once during the study period.
All those clients who have a contact with treatment centres but do not subsequently enter
any treatment program, do not have to be enrolled.
The study population will include a retrospective cohort group entering health service
centres since .......... to .......... and a prospective cohort component of opiates users entering the same
facilities from  .......... to .......... .              
* Definition of "case" is according to the definition adopted by the REITOX working group
(group 3.2) dealing with the improvement of comparability between national treatment reporting
systems. For the purpose of treatment demand, the following definitions, "start", "entry", and
"demand" are considered synonymous.
4. Inclusion criteria for the enrollment
Inclusion criteria to be enrolled into the cohort are the following:
a. opiates use ( by injection or other )
b. starting treatment during the defined recruitment period
c. availability of data for ascertaining vital status
- name and surname (or other identifiers such as social security number)
- date and place of birth
- place of residence (where necessary to ascertain vital status)
- date of entry into treatment centres
For each individual the date on which observation begins will correspond to the date of
entry treatment centre: if a subject applies to different centres or refers to a centre more than once
during the recruitment period, the date of entry into the study will correspond to the less recent one
(when he/she refers to the treatment centre for the first time during the study period).
The date of entry treatment centres will have also to be obtained to distinguish "incident"
and "prevalent" cases at the beginning of the study (at the moment of enrollment).
All centres will provide data describing characteristics of the original study population
together with the reasons for esclusion.
5. Confidentiality
Each centre will have to adopt specific and effective procedures to ensure the absolute
confidentiality of the information gathered. The data on drug users enrolled will have to be managed
by a limited number of people, all of whom will be bound by official secrecy. Methods to ensure
confidentiality could be proposed and discussed by those centres in which specific procedures have
already been adopted and tested.
The identifiers are only necessary to ascertain vital status: all data analysis and reporting will
be done without identification of anyone individual's name and drug use status and concomitant
health effects.
6. Data collection
A standardized data form will be developed for gathering information from patient records
available at the participating treatment centres in order to produce a standard data record structure.
The same data form will be used to collect information from both prospective and retrospective
cohorts.
The data to be collected from clinical records at health facilities in which the subjects
attended will include:
 data necessary to assess vital status:
- name and surname or other identifiers such as social security number
- date and place of birth
- place of residence (where essential to assess vital status)
 gender
 legal nationality
 date of entry into treatment centre
 type of drug used (the one that currently predominantly maintains the addiction)
 route of administration
 frequency of use
 other drugs used
 marital status
 educational level
 employment status
 major occupation
 age at first injection (specify: ever/currently )
 first treatment ever (yes/no)
 scenario of treatment
 data on specific laboratory test (HIV, HBSAg, HCV...) performed.
 date of last contact with treatment centre
 vital status
 date of death
 cause of death
Another issue discussed in the expert meeting was the opportunity of defining some
indicators to be included in the analysis, to take into account the different treatment policies
(scenario) of each country, city or center included in the study. It has been suggested to take into
consideration the work done for the WHO-multi-city study and other experiences in this field. A
specific task of the feasibility study will be to develop an instrument to build such indicator.
7. Feasibility study
The purposes of the feasibility study are:
 to define the type of drug user (only opiates users or other) to be enrolled in the study
 to identify the recruitment site/s (treatment centres, outside treatment centres)
 to develop an instrument to classify each centre included in the study according to the treatment
policies and other relevant characteristics to be considered in the analysis
 to investigate the availability of data required in the countries and in the centres   participating
in the mortality study
 to develop a standard basic data record structure to be produced by each centre
From each potential participating country should be analyzed:
a. the  availability of  birth and death registers, or alternative ways of ascertaining vital status of
residents and their reliability;
b. the availability of centres recruiting drug users and the possibility of access to health records
of drug users at treatment centres;
c. the availability of access to death certificate;
d. the overall expected characteristics of the population of drug users to be enrolled in the 
study.
8. Follow-up
Each centre will be responsible of ascertaining vital status and cause of death.
Follow-up will start for each opiates user enrolled from the time of entry into the cohort (the date
of entry into treatment centre) to the end of the study period or to the date of death. There are
different options to treat losses to follow-up in the analysis. The more  conservative approach
consists of assuming losses to follow-up alive at the end of the study period.
The vital status will be ascertained through the population registers of the last municipality
of residence at the end of the follow up; if population registers will not be available, different
sources of vital status data will be used  i.e. national, regional and local mortality registers (in this
latter case all subjects not found are supposed to be alive). However, for each country the
characteristics of the source and the extent of accuracy of vital status data will have to be described.
The validity of a cohort study depends on complete ascertainment of the events of interest
and correct computation of the population at risk. Major accuracy should be put in tracing subjects
especially as regards migrant drug users and in limiting the proportion of losses to follow up to a
maximum of 5% of the subjects enrolled.
Cause of death will be ascertained through record linkage with general population mortality
files, if available, or through death certificate revision. A 90%-95% cause of death determination
rate in the study population is a desiderable target.
To compare cause specific mortality among drug users in different countries, coding of the
cause of death should be made according to the last revision of the International Classification of
Diseases (ICD).
Causes of death will be classified by a nosologist trained in the rules specified by the ICD
volumes. A cross-validation study will be also planned as satellite product of the mortality study.
9. Data Analysis
The quality and completeness of each form will have to be checked before the data are
entered in a database (the standard structure of the database will be agreed taking into account the
essential data to be collected in each centre) for the purpose of correcting errors where possible and
of verifying any data not supplied.
Data analysis will include a number of analytic strategies. One aspect of analysis will
involve calculation of person-years at risk of dying; each subject will be considered from the date
of first enrollment through the end of the study period, or to the date of death or loss to follow up.
- Local analysis
Direct standardized rates will be calculated for each cohort using as a standard the local
population truncated at 15-59 years.
Standardized Mortality Ratios (SMRs) and their 95% confidence intervals will be used to
compare the mortality experience of drug users with that of the national population for the same
age, sex and period. The expected numbers of deaths will be calculated using sex and age
specific local mortality rates.
- Pooled analysis
Direct standardized rates will be calculated for each cohort using as a standard the European
population truncated at 15-59 years (or the person-years at risk of the pooled cohort) for making
temporal and geographical comparisons.
The analysis of the heterogeneity of mortality could be conducted by using Poisson Regression
and including as covariates both individual data and geographical indicators.
TABLES
The following tables summarize the information obtained both during the seminar and
through the questionnaire from the experts of  European Countries attending the meeting.
In particular table 1 describes the availability of the sources of data to ascertain vital status (on
national and local level) and their accessibility.
Table 2 summarizes some information on the feasibility of conducting prospective and
retrospective mortality cohort study and on the recruitment of drug users to be followed-up.
TABLE 1a  : SOURCES TO ASCERTAIN VITAL STATUS AND CAUSE OF DEATH (AVALAIBILITY AND ACCESSIBILITY)
National / local National / local Accessibility to Code of Other sources
Country City birth registers death registers national / local registers cause of death of vital status/cause of death
Austria Vienna yes / yes yes / yes yes ICD  IX no
Denmark yes / yes / yes 1969 -1993:  ICD VIII no
1994 --->:  ICD  X no
France yes / yes / For death registers only ICD  IX; from 1997: ICD  X no
anonymous data
Finland yes / yes / yes up to 1995:  ICD  IX Register on hospital admissions
from 1996:  ICD  X Register on post mortem toxicology
Germany Hamburg yes / yes yes / yes yes ICD  IX Drug -related death national
registers
(Monocausal understanding) (police authorities)
Documentation by Forensic
Institutes
(not on national level)
Greece yes / yes yes / yes yes Certificate of death no
Italy yes / yes yes / yes yes ICD  IX
TABLE  1b: SOURCES TO ASCERTAIN VITAL STATUS AND CAUSE OF DEATH (AVALAIBILITY AND ACCESSIBILITY)
National / local National / local Accessibility to Code of Other sources
Country City birth registers death registers national / local registers cause of death of vital status/cause of
death
Portugal yes / yes / yes ICD  IX Deaths from overdose
at the Forensic Department
Spain Barcelona yes / yes yes / yes yes ICD  IX Coroner's registers
(and major cities) (all violent deaths)
The
Netherlands
Amsterdam yes / yes yes / yes yes, but death register do not Hospital records, discharge letters, Drug department of the
provide/have information on coroner’s report, information from Municipal Health Service
cause of death general practitioners Local organization for
foreign DUs
United
Kingdom
yes / yes / yes yes
England / Wales
Ireland Eastern Health yes / yes yes / yes yes ICD  IX
Board Area ICD  X: to be introduced in 1998 Coroners' ; police data
Luxembourg  yes / yes / yes No ICD codes (maybe in 1999)
Data on death certificate
Sweden yes / yes yes / yes yes ICD  IX; from 1997 ICD  X no
2TABLE 2a: INFORMATION ON AVAILABILITY OF DATA ON DRUG USERS AND FEASIBILITY OF COHORT MORTALITY STUDY
Country Accessibility to health Possibility for conducting Drug users Only in Treatment centres to be included
record of drug users prospective / retrospective in treatment/not in treatment methadone treatment
cohort study
Austria  (Vienna) yes ? / ? yes / yes Centres for methadone mainten
programs
Denmark no yes / from 1995 yes / yes General practice
France no ? / no Specialized centres in drug
addiction
treatment
Finland yes (From 1987 Personal
Data
yes / yes yes / ?
File Act limits linkage among
different registers)
Germany yes yes / from 1990 yes / yes Outpatient’s department for drug
abuse
(Hamburg) Psychiatric Department (Hospital)
Psychotherapeutic Department for
drug abuse
Prisons of Hamburg
Greece yes yes / yes Yes / prison yes Methadone treatment centre
Italy yes yes / yes yes / Public Treatment Centres
Non Governmental Organizations
TABLE 2b: INFORMATION ON AVAILABILITY OF DATA ON DRUG USERS AND FEASIBILITY OF COHORT MORTALITY STUDY
Country Accessibility to health Possibility for conducting Drug users Only in Treatment centres to be included
record of drug users prospective / retrospective in treatment/not in treatment methadone treatment
cohort study
Portugal yes yes / yes yes / no Treatment centres for addiction
Spain yes yes / from 1992 yes / emergency, prison ? Public non-residential treatment
centre
(major cities)
The Netherlands not direct yes / yes / yes Low threshold methadone mainten
programs
(Amsterdam)
United Kingdom yes yes / yes yes / ?
Ireland yes At regional level:   yes / yes yes / ? Statutory, drug free; primary care
psychiatric
from 1994 services; voluntary + community
agencies
Luxembourg yes yes / yes;   from 1994 yes / ? Specialized treatment centres (all)
Sweden no yes / yes Inpatient treatment at general and
psychiatric
from 1961 to 1995 hospitals
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Annex 2
Questionnaire for investigating the availability of the data required to carry out cohort
study on mortality of drug users in European Countries
1. Name of country ..............................................................................................................
If procedure differs from Region to Region, please fill in one questionnaire for each Region
2. Name of Region ..............................................................................................................
3. Are there in your country national birth and death registers?
yes no
4. Are there in your Region local birth and death registers?
yes no
5. Could you have access to national or regional birth and death registers?
yes no
6. How causes of death are codified?
.........................................................................................................................................
.........................................................................................................................................
.........................................................................................................................................
7. Are there in your country or Region other sources of data to ascertain vital status and cause of
death?
yes specify ..........................................................................
no
8. Could you access to health records of drug users at treatment centres?
yes no
9. Would you consider feasible to conduct a mortality cohort study in your country (Region)?
a. prospective yes no don't know
b. retrospective yes no don't know
10. The cohort could be followed for mortality
from to
  year    year
11. Indicate the approximate percentage of completeness of follow-up of the cohort anticipated:
a. for prospective cohort %
b. for retrospective cohort %
12. What could be the approximate length of time required to obtain the ascertainment of vital status
and cause of death?
months
13. What kind of treatment centres could be involved in the cohort study?
................................................................................................................
................................................................................................................
................................................................................................................
14. What kind of treatment strategies are adopted in treatment centres? (specify the percentage of
subjects treated)
- methadone detoxification programmes
- methadone maintenance programmes
- other pharmacological treatments (specify)
  ........................................................................
  ........................................................................ 
- drug free programmes
